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Developmental Maturation within the Hematopoietic System 
 
Abstract 
 
Stem cell biologists creating cells and tissues for therapies, disease modeling, and drug screening 
have observed that differentiating pluripotent stem cells (PSCs) tend to produce cells at an embryonic 
stage of development but have difficulty maturing into adult definitive cells.  A better understanding of 
developmental maturation will provide insights into embryogenesis and permit more accurate disease 
modeling.  In the hematopoietic system, primitive and definitive cells are distinguished by functional 
transplantation assays, well characterized cell surface antigens, and gene expression signatures.  We 
examined the transition in vivo in transplanted murine hematopoietic stem cells (HSCs) and in vitro in 
human PSC (hPSC) derived red blood cells (RBCs).  We found that the hematopoietic microenvironment 
of the recipient significantly affects the outcome of HSC transplantation.  The earliest embryonic HSCs 
perform better in neonatal recipients, whereas more mature adult-like HSCs perform better in adult 
recipients.  The preference may be related to different active hematopoietic niches in neonates and 
adults, as we observed adult HSCs homing to different tissues in neonatal and adult recipients.  
Additionally, we found that proliferation may enhance the neonatal engraftment potential of adult-like 
HSCs.  Our data highlight the importance of the host environment on transplantation outcomes, and 
point to the neonatal transplant model as a tool to functionally examine the earliest HSCs and primitive 
derivatives of PSCs. 
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We also investigated the maturation of RBCs derived from hPSCs and found that the RBC lineage 
derived in vitro is exclusively primitive. Exogenously expressing key transcription factors or adding 
stromal co-cultures during differentiation did not force the cells to mature to the definitive state, 
suggesting that culture conditions play a significant role and presently lack essential cues for the 
emergence of definitive hematopoietic cells.  Additionally, the generated cells did not survive to 
contribute to the erythroid lineage when transplanted into a supportive in vivo environment.  The 
system we optimized for differentiation of hPSCs into RBCs can be used to screen other factors to 
promote maturation to the definitive fate.  Collectively, these data highlight the role of the 
microenvironment in determining the degree of developmental maturation of HSCs and their progeny.   
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Chapter 1 
Introduction 
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1.1 Primitive hematopoietic derivatives of pluripotent stem cells 
 
For decades hematologic diseases, ranging from sickle cell anemia to leukemia, have been 
treated and/or cured by giving patients normal blood cells, which come from donated bone marrow, 
donated peripheral blood, or cord blood.  Every year tens of thousands of patients in the United States 
depend on the availability of donor cells and a compatible donor cannot be found for 30% of patients 
[2].  Recent discoveries point to a potential alternative source of hematopoietic cells for therapy: human 
pluripotent stem cells (hPSCs).  PSCs are derived from the inner cell mass of a blastocyst, called 
embryonic stem cells (ESCs), or somatic cells reprogrammed with exogenous expression of OCT4, SOX2, 
KLF4, cMYC, called induced pluripotent stem cells (iPSCs) [3-6].  hPSCs can be differentiated into many 
hematopoietic cells including hematopoietic stem cells (HSCs) and red blood cells (RBCs).  Unfortunately, 
state of the art differentiation methods produce primitive cells that closely resemble the earliest 
hematopoietic cells in the embryo.  In order to use hematopoietic derivatives of hPSCs for therapies, 
drug screening, or disease modeling, the cells need to be more mature, committed to the definitive fate 
as seen in hematopoietic cells in adults.   
There is a major knowledge gap in the field in understanding the cell of origin and mechanism 
giving rise to definitive cells and how the mechanism differs from the emergence of primitive cells.  
There are also open questions surrounding the differences between primitive and definitive cells in 
response to the environment.  
We made strides towards answering some of these questions in two systems: 1) maturation of 
embryonic HSCs or their precursors in murine neonates and 2) human induced pluripotent stem cells 
(hiPSCs) directly differentiated into RBCs in vitro.  The murine hematopoietic system closely mimics the 
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human system, and provides an excellent model organism to functionally assay hematopoietic cells by 
transplantation. 
 
1.2 Murine hematopoietic stem cell ontogeny 
 
HSCs sit atop the hematopoietic hierarchy with the ability to self-renew and differentiate to 
generate all types of hematopoietic cells.  HSCs are functionally defined by the ability to give rise to 
long-term multi-lineage reconstitution [7-10]. There is a debate amongst developmental hematologists 
as to when and where the first HSC arises in the murine embryo.  Strong evidence supports the 
emergence of HSCs from the hemogenic endothelium of the para-aortic splanchnopleura/aorta-gonad-
mesonephros (PSp/AGM) between embryonic day 9.0 (E9.0) and E11.5 [11, 12].  At E12.5, driven by an 
unknown mechanism, HSCs migrate to the fetal liver, where the stem cell pool expands [13-15].  The 
HSC niche in the fetal liver that promotes rapid proliferation has not been extensively studied.  
Beginning at E18.5, a loosely characterized mechanism prompts HSCs to seed the bone marrow, where 
they remain throughout the adult life of the mouse [16-20].  The prevailing hypothesis is that interaction 
with specific niches during development allows embryonic HSCs to mature into adult HSCs [21, 22].  
Whereas the niches in the adult bone marrow that support HSC and progenitor function and 
maintenance are well studied and known to include CAR cells, mesenchymal stem cells, endothelial cells 
and osteolineage progenitors [23], the niches that support developmental maturation of HSCs are 
largely unstudied.   
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1.3 Developmental changes in murine hematopoietic stem cells 
 
HSCs from different stages of development are not identical.  HSCs emerging from the AGM 
tend to undergo more symmetric than asymmetric divisions to generate more HSCs.  HSCs in the fetal 
liver are rapidly cycling to build up the stem cell pool for the organism, whereas HSCs in the adult bone 
marrow are mostly quiescent, largely allowing progenitors to maintain homeostasis.  Also, the earliest 
HSCs do not have the same surface antigen profile as more mature HSCs, which suggests additional 
functional differences.  E11.5 AGM HSCs can be prospectively isolated as VE-Cadherin+ CD45+ CD34- 
cKitlow Sca1+ CD31low, while a nearly pure population of fetal liver and adult bone marrow HSCs is 
Lineage- Sca1+ cKitlow CD150+ CD48-  [24-27].   
 
Table 1-1: Early Embryonic HSCs in Different Transplant Models 
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The earliest HSCs also have different engraftment potential in various transplant models (Table 
1-1).  In lethally irradiated wild-type adult mice, the current gold standard functional assay, limiting 
dilution transplants predicted 1 HSC in the AGM of each E11.5 embryo.  E10.5 AGM rarely engrafts wild-
type adult mice, and no engraftment from E9.5 PSp has been reported in wild-type adult mice [19, 28, 
29].  However, if the host environment is altered by transplanting into immunodeficient adult mice, then 
E10.5 AGM and even E9.5 PSp can engraft [30].  These early HSCs can also engraft a second model 
system: wild-type neonatal recipients [31].  Cells from E9.5 PSp and even E9.0 yolk sac give long-term 
multi-lineage engraftment in wild-type neonates and can reconstitute secondary recipients [32-35].  
These different transplant models can be used to further our understanding of the earliest HSCs, how 
they emerge, what signals and environment they need to survive and mature, and how they differ from 
more mature HSCs. 
Within engrafting adult-like HSCs, there is heterogeneity in terms of contribution to myeloid and 
lymphoid lineages.  Eaves and colleagues identified 4 types of HSCs in fetal liver and adult bone marrow 
based on relative lineage contributions [36, 37].  While all 4 types are detectable in fetal liver, β-HSCs 
are dominant and α-HSCs are rare.  Once the bone marrow is established at E18.5, the number of α-
HSCs increases until it is half of the β-HSCs.  This ratio is present in the bone marrow of 3-week-old mice 
and remains in adult bone marrow, suggesting the bone marrow stimulates the increase in α-HSCs.   
 
1.4 Developmental changes in lineage committed hematopoietic cells 
  
 Like HSCs, mature lineage committed hematopoietic cells have characteristics unique to 
embryonic and adult hematopoiesis.  In B-cell lymphopoiesis, B-1a cells are seen in transplants of 
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neonatal liver, whereas B-2 cells are observed in transplants of both neonatal liver and adult bone 
marrow [38].  Splenic marginal zone B-cells have a fetal origin [39, 40].  In T-cell lymphopoiesis, fetal T-
cells express the Vγ3 Vδ1 or Vγ4 Vδ1 T-cell receptors, while adult T-cells express Vγ2 or Vγ5 [41, 42].  
Fetal monocytes have increased expression of tissue-degrading enzymes, scavenger receptors, and 
chemokines and, unlike adult cells, can transition from CD14low CD16- precursors to CD14high CD16+ 
without passing through a CD14high CD16- intermediate [43].  Fetal and adult megakaryocytes undergo a 
similar process to produce platelets, but fetal megakaryocytes release platelets when the cells have 
lower ploidy and are smaller [44-47].  Erythrocytes produce different hemoglobins during 
embryogenesis and in adulthood, which will be described in detail in sections 1.5 and 1.6. 
 
1.5 Human erythropoiesis 
 
Erythropoiesis occurs in two waves: primitive and definitive. Large nucleated primitive 
erythroblasts containing ε-globin arise in the yolk sac and provide the embryo with RBCs until definitive 
cells residing in the fetal liver and begin producing fetal definitive RBCs containing γ-globin.  This 
constitutes the first globin switching event in humans.  A second globin switching event occurs as the 
bone marrow becomes the main site of definitive hematopoiesis and results in RBCs containing β-globin 
[48]. Other than hemoglobin expression and size, primitive and definitive RBCs also differ by i/I 
expression, expression of δ-globin, carbonic anhydrase content, and the level of activity and function of 
phosphofructokinase [49]. 
HSCs differentiate into many mature cell types including enucleated RBCs.  Differentiation into 
RBCs goes through six identifiable stages during which hemoglobin protein is accumulated and the 
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nucleus compacts to eventually be extruded from the cell leaving a 6-8 µm mature RBC [50].  Cell 
surface antigens Band 3 and α4-integrin can be used to identify and purify cells at each stage [51].   
 
1.6 Globin switching 
 
The β-globin locus, positioned on human chromosome 16, contains five different hemoglobin 
genes arranged in the order they are expressed during development.  The mechanisms regulating gene 
expression at the β-globin locus are not completely understood.  The looping model of globin regulation 
proposes that the distal locus control region (LCR) loops around to bring activator proteins in proximity 
to proteins at the promoter of each globin gene for transcriptional activation [52-55].  A dual mechanism 
combining autonomous gene control and gene competition for interaction with the LCR upstream of the 
globin locus has been proposed to explain globin switching [56, 57].  When only proximal cis- regulatory 
elements are present, the globin genes are expressed at the correct developmental stage and in the 
proper tissue but in a position dependent fashion [58-61].  These observations suggest autonomous 
gene control.  However, that is not the only mechanism in action.  It has been proposed that at the time 
of the second globin switch from γ-globin to β-globin, a flip-flop mechanism allows a dynamic expression 
of both γ-globin and β-globin until repressive factors autonomously silence γ-globin expression [62].  
Then, β-globin expression increases, and it remains the predominant globin throughout adulthood.  This 
suggests a possible competition between the two globin genes for interaction with the LCR.  Many 
transcription factors and complexes including BCL11A, KLF1, SOX6, GATA1, NF-E4, COUP-TF, IKAROS, 
DRED, and MBD2 are known to bind the β-globin locus, but the exact mechanism regulating globin 
expression is unknown [63-75]. 
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1.7 Directed differentiation of hPSCs cells to RBCs  
 
 Before using human PSCs for cell therapy, it must first be possible to differentiate human 
PSCs into the desired cell type.  Many groups have attempted to recapitulate in vivo erythropoiesis by 
differentiating hESCs into RBCs in vitro (Table 1-2) [1].  Directly differentiating human PSCs into 
definitive RBCs has proven challenging.  It is possible to generate large numbers of primitive immature 
RBCs, but generating definitive adult-like RBCs has proven elusive for the field.  The cells accumulate 
hemoglobin, appear red in color, and bind oxygen.   They mature appropriately as measured by cell 
surface markers CD71 and GPA, but remain mostly nucleated and have a primitive hemoglobin 
expression pattern, expressing ε-globin and γ-globin with little or no β-globin.  The system from Lu et al. 
is the only one with serum free conditions without co-culture.  They generate few erythroid cells that 
have the capacity to express low levels of β-globin but still express high levels of γ-globin and ε-globin 
[76].  MacLean et al. comes the closest to generating mature definitive RBCs.  They generate cells 
producing mostly γ-globin, but the RBC yield is low.  An unanswered question in the field is what 
mechanism will drive the switch from primitive to definitive RBCs in vitro.   
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This thesis highlights the affect of the environment on the ability of hematopoietic cells to 
mature to the adult definitive fate.  In Chapter 2 we test the hypothesis that neonates are more 
permissive hosts for hematopoietic stem cell transplants and provide insights to the mechanism 
governing the preference of HSCs for different hosts.  In Chapter 3 we examined the potential of human 
pluripotent stem cell derived RBCs to mature to definitive RBCs. 
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2.1 Abstract 
 
The first hematopoietic stem cells (HSC) that engraft irradiated adult mice arise in the aorta-
gonad-mesonephros (AGM) on embryonic day 11.5 (E11.5). However, at this stage there is a discrepancy 
between the apparent frequency of HSCs suggested by imaging and their rarity when measured by 
limiting dilution transplant. We have attempted to reconcile this difference using neonatal recipients, 
which are more permissive for embryonic HSC engraftment. We found that embryonic HSCs from E9.5 
and E10.5 preferentially engrafted neonates, whereas developmentally mature, definitive HSCs from 
E14.5 fetal liver or adult bone marrow more robustly engrafted adults. Neonatal engraftment was 
enhanced after treating adult bone marrow-derived HSCs with interferon.  Adult bone marrow-derived 
HSCs preferentially homed to the liver in neonatal mice yet showed balanced homing to the liver and 
spleen in adults.  As more receptive hosts, neonates enable detection and quantification of emerging 
definitive HSCs as early as E9.5. 
 
2.2 Introduction 
 
According to the classical definition, a definitive HSC reconstitutes multi-lineage hematopoiesis 
long-term in irradiated adult primary transplant recipients, and can be serially passed into secondary 
recipients, indicating the capacity for both self-renewal and multi-lineage differentiation [1-4]. Under 
that definition, the first transplantable murine HSC emerges in vivo in the AGM at E11.5 [5-9].  HSCs then 
migrate to the fetal liver and rapidly divide to build up the stem cell pool. Ultimately, HSCs populate the 
developing bone marrow where they become quiescent once homeostasis is reached in the post-natal 
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period.  Interaction with specific niches during development allows embryonic HSCs to mature into adult 
HSCs [10, 11]. 
The surface antigen profile of the engrafting cell at E11.5, as identified by transplantation, is VE-
Cadherin+ CD45+ CD34- cKitlow Sca1+ CD31low [12, 13].  Imaging techniques coupled with the cell surface 
profile of the engrafting cell have provided insight into the emergence of the definitive HSC [14-17].  
Imaging has revealed hundreds of c-Kit+ clusters in E11.5 AGM, implying a discrepancy in the quantity of 
potential HSCs identified by imaging relative to the frequency defined by limiting dilution 
transplantation in adult recipients. 
Analysis of emerging hematopoietic cells in the AGM at E10.5 shows 1.7 Sca1+ c-Kit+ CD31+ 
CD41+ cells per embryo [16].  Transplantation has revealed that E10.5 AGM cells are capable of rare 
long-term multi-lineage repopulation of wild-type adult recipients (3% of transplanted animals) and 
more robust repopulation in immunodeficient adult recipients, indicating that the host environment 
plays a critical role in detection of nascent HSCs [8, 18, 19].  Interestingly, VE-Cadherin+ CD45- cells from 
E10.5 AGM robustly reconstitute wild-type adult recipients after 4 days of ex vivo culture, further 
suggesting that there are cells in the AGM at E10.5 with enhanced potential to engraft if cultured under 
proper conditions [20]. 
Before E10.5, the tissues of the para-aortic splanchnopleura (PSp) contain progenitors that are 
primed to give rise to the definitive HSC, as per the classical definition [8, 21, 22]. A population from 
E9.5 PSp has been reported to engraft immunodeficient adult recipients and wild-type neonatal 
recipients [23-25].  Neonatal engraftment has also been observed from E9.0 yolk sac [26, 27], suggesting 
that the neonate may be more permissive for engraftment of early embryonic HSCs.  In this study we 
utilized the neonatal transplant model to quantify nascent definitive HSCs in the earliest intraembryonic 
tissues to date, and confirm the more permissive environment of the neonatal recipient.  Interestingly, 
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we also found that definitive adult HSCs engraft less robustly in the neonate relative to the adult.  Our 
data demonstrate the significant impact of the recipient on the outcome of HSC transplantation, and 
define distinct survival and engraftment requirements for adult HSCs. 
 
2.3 Results 
 
We first compared engraftment of neonates and adults with cells from E11.5 AGM, the earliest 
population reported to engraft wild-type adult recipients. Neonatal recipients proved to be more 
permissive for engraftment than adult recipients with similar conditioning.  Whereas 7/9 neonatal 
recipients were engrafted with 1ee, at most 3/6 adult recipients receiving sub-lethal irradiation and no 
helper cells were engrafted at low levels (Figure 2-1 A and Table 2-1). Neonates transplanted with E11.5 
AGM and helper cells were engrafted at levels similar to those transplanted without helper cells, 
indicating that the helper cells are not responsible for the low level engraftment observed in adult 
recipients (Figure 2-2).  Three of 11 neonates transplanted with 0.25 embryo equivalents (ee) showed 
long-term engraftment (Figure 2-3 A and B).  Secondary transplants demonstrated donor HSC self-
renewal when taken from primary animals with multi-lineage reconstitution (Figure 2-3 C), but three 
primary recipients with long-lived myeloid biased lineage skewing did not engraft secondary recipients, 
and thus were not engrafted with a self-renewing HSC (Figure 2-3 B).  We also compared neonatal 
engraftment with E11.5 AGM to the current gold standard of lethally irradiated adult recipients 
receiving helper cells.  Only 1/8 adult mice was engrafted (Table 2-1). Before quantitative analysis, these 
data suggest the neonatal transplant assay is a more permissive functional test for early embryonic 
HSCs, and the preference for neonatal recipients is even more marked when compared to the gold 
standard assay. 
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Figure 2-1 
 
Figure 2-1: Neonates are more permissive for engraftment of early embryonic HSCs.  A) Adult (circle) 
and neonatal (square) recipients were both transplanted with 1ee of whole E11.5 AGM.  Neonatal 
recipients were transplanted with limiting doses of B) whole E10.5 AGM and C) whole E9.5 PSp.  The 
numbers in the graph legends reflect the number of animals engrafted over the number of animals 
transplanted. 
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Figure 2-2 
 
Figure 2-2: Helper cells in neonatal transplant model. Neonates received 2ee or 1ee of E11.5 AGM along 
with 500,000 whole bone marrow cells as helper.  Data shown are 18 weeks post-transplant.  
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Figure 2-3 
 
Figure 2-3: Multi-lineage reconstitution and self-renewal capacity of early embryonic HSCs.  A) Neonatal 
recipients were transplanted with limiting doses of whole E11.5 AGM.  The numbers in the graph legend 
reflect the number of animals engrafted over the number of animals transplanted. B) Lineage 
breakdown of donor contribution in peripheral blood at 18 weeks post-transplantation for neonates 
engrafted with E11.5 AGM.  C) Secondary transplants were carried out for primary recipients engrafted  
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Figure 2-3 (Continued)  
with early embryonic HSCs.  Lineage breakdown of donor contribution in peripheral blood at 18 weeks 
post-transplantation for neonates engrafted with D) E10.5 AGM and E) E9.5 PSp.     
 
Table 2-1: Neonatal engraftment from early embryonic HSCs.  The threshold for engraftment was drawn 
at 1%.  Percent engraftment was calculated using only engrafted mice.  P-values are between neonatal 
and adult recipients transplanted with the same donor population and calculated using Fisher’s exact 
test.  ND – not determined. 
 
 
 
Donor Recipient 
Irradiation 
Dose (Gy) 
Number of 
Animals 
Engrafted 
Number of 
Animals 
Transplanted 
Percent 
Animals 
Engrafted 
Average 
Percent 
Donor 
Chimerism 
p-
value 
E11.5 
1 ee Adult 3.5 2 6 33.3 3.4 ND 
1 ee Adult 6.5 3 6 50 2.1 ND 
1 ee Adult 10 1 8 12.5 34.2 
0.015 
1 ee Neonate 3.5 7 9 77.8 6.9 
E10.5 
1 – 7  
ee 
Adult 10 0 20 0 0 
0.0018 
1 ee Neonate 3.5 5 10 50 11 
E9.5 
 Adult 10 ND ND ND ND 
ND 1 – 8  
ee 
Neonate 3.5 5 53 9.4 5.7 
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Figure 2-4 
 
Figure 2-4: Adult engrafting subpopulations also engraft neonatal recipients.  A) FACS plot of E11.5 AGM 
fractionated by VE-Cadherin and CD45.  B) Neonatal recipients transplanted with unfractionated, VE-
Cadherin + CD45+, or VE-Cadherin+ CD45- cells from E11.5 AGM.  The numbers in the graph legend reflect 
the number of animals engrafted over the number of animals transplanted. 
 
VE-Cadherin+ CD45+ cells from E11.5 AGM have been reported to engraft adult recipients [13].  
Similarly, we found that the VE-Cadherin+ CD45+ but not the VE-Cadherin+ CD45- compartment engrafted 
neonates, thus demonstrating that neonates and adults are engrafted with the same cells from E11.5 
AGM (Figure 2-4 B).  However, the predicted repopulating cell frequency was higher in neonatal than 
adult recipients. Using the neonatal transplant model, limiting dilution analysis (LDA) predicted 1 
repopulating cell in 0.935 ee, thus quantifying the sensitivity of the neonatal system for engraftment of 
embryonic HSCs (Table 2-2).  In our hands using the adult transplant model with 300,000 helper cells, 
LDA predicted 1 repopulating cell in 5.7 ee of E11.5 AGM, whereas the published frequency using adult 
recipients is approximately 1 per ee [5] (Table 2-2).  When we replicated the conditions from 
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Kumaravelu et al. using 20,000 helper cells, the calculated frequency was 1 repopulating cell in 0.538 ee 
(Table 2-2). Thus, our experimental quantifications reveal sensitivity in the adult transplant model to 
helper dose and no preference of HSCs at E11.5 for neonatal recipients.   
 
Table 2-2: Early embryonic but not adult-like HSCs prefer neonatal recipients.  LDA of reconstitution of 
neonatal and adult recipients with adult bone marrow LT-HSCs, E14.5 fetal liver LT-HSCs, whole E11.5 
AGM, whole E10.5 AGM, and whole E9.5 PSp.  The upper and lower limits provide the 95% confidence 
interval for the repopulating cell frequency.  The goodness of fit tests how well the data fit the single-hit 
model that one repopulating cell will give a positive signal.  A value of 1 suggests a good fit, less than 1 
suggests heterogeneity in the donor cell population, and greater than 1 suggests a multi-hit model 
where recipients are hypersensitive to the given dose of donor cells.  P-values are between neonatal and 
adult recipients transplanted with the same donor population and were calculated by the LDA 
algorithm.  ND – not determined. 
Donor Recipient 
Helper 
Cell 
Dose 
Estimated 
Repopulating 
Cell 
Frequency 
Frequency 
Upper 
Limit 
Frequency 
Lower 
Limit 
Fit 
Single-
hit 
Model 
p-
value 
BM LT-
HSCs 
Adult 300,000 1/13.1 cells 1/6.19 1/27.7 0.96 3.33E-
8 Neonate None 1/177 cells 1/100 1/313 1.2 
FL LT-
HSCs 
Adult 300,000 1/25.7 cells 1/13.8 1/47.6 0.55 3.07E-
4 Neonate None 1/114 cells 1/66.9 1/195 0.91 
E11.5 
AGM 
Adult 
20,000 1/0.538 ee 1/0.24 1/1.2 -4.46  
300,000 1/5.7 ee 1/2.16 1/15 2.6 5.12E-
5 Neonate None 1/0.935 ee 1/0.624 1/1.4 0.74 
E10.5 
AGM 
Adult  ND ND ND ND 
ND 
Neonate None 1/2.84 ee 1/1.6 1/5.02 0.71 
E9.5 
PSp 
Adult  ND ND ND ND 
ND 
Neonate None 1/44.8 ee 1/18.4 1/109 -0.212 
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We then evaluated the engraftment potential of newly specified HSCs from earlier stages of 
ontogeny. Neonates showed robust, long-term, multi-lineage reconstitution from 4 ee to 1 ee of 
unfractionated E10.5 AGM (30-39 somites) (Figure 2-1 B and Figure 2-3 D).  At 18 weeks post-transplant, 
3/5 recipients receiving 4 ee, 5/10 receiving 2 ee, and 5/10 receiving 1 ee showed multi-lineage 
engraftment with an average of 28%, 22%, ad 11% donor contribution, respectively.  No neonates were 
engrafted with 0.5 ee.   In comparison, no engraftment was observed in adult recipients receiving up to 
7 ee with as few as 20,000 helper cells (Table 2-1). Secondary transplants demonstrated self-renewal 
capacity of the repopulating donor cells from E10.5 AGM (Figure 2-3 C). LDA predicted 1 repopulating 
cell in 2.84 ee of E10.5 AGM when using the neonatal transplant model (Table 2-2), indicating that the 
repopulating cell is less abundant in the AGM at E10.5 than it is at E11.5. These data establish that 
whole E10.5 AGM robustly reconstitutes neonatal but not adult recipients, and demonstrate the 
existence of an HSC capable of long-term multi-lineage reconstitution in the AGM of some embryos as 
early as E10.5.   
When we examined reconstitution potential from even earlier in ontogeny, we detected long-
term multi-lineage donor chimerism from unfractionated E9.5 PSp (16-26 somites) transplanted into 
neonates in doses from 8 ee to 1 ee (Figure 2-1 C and Figure 2-3 E).  At 18 weeks post-transplant, 1/16 
recipients receiving 8 ee, 2/5 receiving 5 ee, and 2/13 receiving 1 ee were engrafted at an average of 
15%, 5%, and 2%, respectively.  Curiously, mice engrafted with E9.5 PSp showed an early B-cell skewing, 
which was not as pronounced in neonates engrafted with E10.5 AGM and not seen with E11.5 AGM 
(Figure 2-3 E).  LDA predicted 1 repopulating cell in 44.8 ee of E9.5 PSp (Table 2-2).  Secondary 
transplants confirmed that the engrafting cell from E9.5 PSp was truly a self-renewing stem cell (Figure 
2-2 C). These findings provide additional conclusive evidence for the existence of an intraembryonic 
repopulating cell as early as E9.5 in some embryos. 
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We next determined if the neonate is a more permissive recipient for all HSCs or only those 
from the early embryo.  LT-HSCs (Lineage- Sca1+ c-Kit+ CD150+ CD48-) from adult bone marrow [28] were 
transplanted into neonatal and adult recipients in doses ranging from 100 cells to 10 cells (Figure 2-5 A 
and Table 2-3).  Surprisingly, adult donor LT-HSCs failed to give rise to robust engraftment in neonatal 
recipients monitored for up to 23 weeks.  Adult recipients were robustly engrafted, whereas 
engraftment in neonatal recipients was minimal.  At 18 weeks post-transplant, all adult recipients that 
received 100 cells and 3 of 5 animals that received 10 cells showed multi-lineage engraftment.  LDA from 
adult recipients predicted 1 repopulating cell in 13.1 LT-HSCs from adult bone marrow, which is less 
frequent than published reports, which used 200,000 helper cells [28].  While considering low-level 
engraftment of neonates, LDA predicted 1 repopulating cell in 177 LT-HSCs (Table 2-2).   
We mined published microarray data of HSCs from E11.5 AGM and adult bone marrow to better 
understand why HSCs from different developmental stages might prefer different transplant hosts [29].  
Modules from the microarray data point to key differences in cytokine-cytokine receptor interaction, 
transcription, metabolism, the toll-like receptor signaling pathway, and membrane composition.  With 
324 differentially expressed genes encoding membrane proteins, we hypothesized HSCs from various 
points in ontogeny may home to unique niches in different hematopoietic tissues. Interestingly, all 
examined genes known to be involved in homing (cxcr4, cd44, connexin-43, cd49d, lfa-1, and psgl1) 
showed consistent expression between E11.5 AGM HSCs and adult bone marrow HSCs.  
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Figure 2-5 
 
Figure 2-5: Neonatal recipients are not permissive for engraftment of all HSCs.  A) Neonatal (circles) and 
adult (squares) recipients were transplanted with 100 adult bone marrow LT-HSCs.  *While in 3 neonatal 
recipients we detected a robust signal in the peripheral blood at a single time point of 18 weeks in one 
experiment, substantially lower donor chimerism was observed in these mice at the next time point of 
23 weeks, and no other experiments showed this phenomenon, leading us to conclude that these data 
may have been a spurious experimental artifact.  B) Neonatal (circles) and adult (squares) recipients 
were transplanted with 100 E14.5 fetal liver LT-HSCs.  C) Neonatal recipients were transplanted with 50 
neonatal liver LT-HSCs (circles) and 50 neonatal bone marrow LT-HSCs (squares).  The numbers in the 
graph legends reflect the number of animals engrafted over the number of animals transplanted. D) 
Quantification of FACS analysis of Ki-67+ LT-HSCs in neonatal liver and bone marrow.  Data shown is the 
mean ± SEM of three experimental replicates with pooled samples.   
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Table 2-3: Neonatal engraftment from adult-like HSCs.  The threshold for engraftment was drawn at 1%.  
Percent engraftment was calculated using only engrafted mice.  P-values are between neonatal and 
adult recipients transplanted with the same donor population.  Statistical analysis for adult BM HSCs was 
performed using Fisher’s exact test, and the student’s t-test was used for fetal liver HSCs and neonatal 
HSCs.  *3/5 animals had robust engraftment that was not seen at any other time point up to 23 weeks 
post-transplant leading us to conclude it may have been a spurious experimental artifact.  ND – not 
determined. 
Donor Recipient 
Number 
of 
Animals 
Engrafted 
Number of 
Animals 
Transplanted 
Percent 
Animals 
Engrafted 
Average 
Percent 
Donor 
Chimerism 
p-
value 
Adult BM 
100 
Cells 
Adult 5 5 100 25.4 
0.033 
100 
Cells 
Neonate 5* 14 35.7 31.4 
E14.5 FL 
100 
Cells 
Adult 6 6 100 77.9 
1.44E-
6 100 
Cells 
Neonate 10 16 62.5 22.7 
Neonatal 
BM 
50 
Cells 
Neonate 4 8 50 17.8 
0.058 
Neonatal 
Liver 
50 
Cells 
Neonate 6 6 100 31.0 
 
 
To determine if a mature definitive HSC population from the fetal liver could engraft neonates, 
we transplanted cells with the same surface antigen profile (Lineage- Sca1+ c-Kit+ CD150+ CD48-) from 
E14.5 fetal liver into neonatal and adult recipients in doses ranging from 100 cells to 10 cells (Figure 2-5 
B and Table 2-3). Adult recipients had high level engraftment at all doses, whereas neonatal 
engraftment was only robust with 100 donor cells.  At 18 weeks post-transplant, 10/16 neonatal 
recipients that received 100 cells showed balanced multi-lineage reconstitution with an average of 
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22.7% donor contribution; whereas only 1/8 neonates transplanted with 50 cells, 2/6 transplanted with 
25 cells, and 1/8 transplanted with 10 cells were engrafted.  LDA from neonatal recipients predicted 1 
repopulating cell in 114 LT-HSCs; whereas from adult recipients LDA predicted 1 repopulating cell in 25.7 
LT-HSCs (Table 2-2).  Thus, while E14.5 fetal liver LT-HSCs engrafted neonates more readily than adult 
bone marrow LT-HSCs, both classes of definitive LT-HSCs from fetal liver and adult bone marrow 
engrafted better in irradiated adults than in neonates. 
To further examine the differences between HSCs residing in the liver versus the bone marrow, 
we transplanted LT-HSCs from neonatal bone marrow and neonatal liver into neonates.  At 18 weeks 
post-transplant, we observed a difference in the engraftment potential; more animals were engrafted at 
higher levels with neonatal liver LT-HSCs (Figures 2-5 C and Table 2-3). More neonatal liver LT-HSCs are 
proliferating than neonatal bone marrow LT-HSCs (Figure 2-5 D).  These data show neonatal 
engraftment potential as well as proliferation decreases around birth in HSCs that have migrated to the 
bone marrow.   
Fetal liver LT-HSCs are rapidly cycling and expanding in the developing embryo, while adult bone 
marrow LT-HSCs are typically quiescent [30-33].  Thus we tested whether proliferation status could 
influence the potential for definitive adult-like HSCs to engraft neonates.  To drive adult-like HSCs into 
the cell cycle, we treated adult mice with interferon-α (IFNα) and 5-FU [34-36]. Cycling HSCs were then 
isolated and transplanted into neonatal recipients (Figure 2-6 A).  HSCs exposed to IFNα were able to 
engraft neonates and adults more robustly than PBS treated controls (Figure 2-6 B).  When HSCs were 
exposed to 5-FU, which has less effect on quiescent HSCs than IFNα [37], we observed no enhancement 
of neonatal engraftment (Figure 2-6 C).  Further analysis of HSCs treated with IFNα and 5-FU through 
published microarrays revealed a multitude of differentially expressed genes, suggesting IFNα and 5-FU 
have very different affects on HSCs, which may explain the difference in neonatal engraftment potential 
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[34, 38].  These data, in addition to the reduction of cycling LT-HSCs in neonatal bone marrow, suggest 
that an active cell cycle enhances neonatal engraftment.   
We also hypothesized that HSCs from different developmental stages home to different 
hematopoietic tissues in neonates and adults, which likely has a significant impact on long-term 
engraftability.  We transplanted LT-HSCs from adult bone marrow into neonatal or adult recipients, and 
after 15 hours recovered and dissociated multiple tissues and surveyed for donor cells by flow 
cytometry.  We chose to examine the recipients 15 hours post-injection to assess homing prior to 
proliferation of the donor cells [39-41]. At 15 hours post-transplant, we detected comparable numbers 
of donor cells in both neonates and adults, indicating that a lack of short-term donor cell survival could 
not account for the failure of adult LT-HSCs to engraft in neonates.  In adult recipients 42% of injected 
cells were detected in the liver, 48% in the spleen, and 8.7% in the marrow of the leg bones.  In neonatal 
recipients, 88% of injected cells were detected in the liver, 4.3% in the spleen, and 6.9% in the marrow 
of the leg bones. Very few or no donor cells were found in the thymus, peripheral blood, or lungs of 
either adults or neonates (Figure 2-7).  These data demonstrate that definitive adult-like HSCs home to 
different tissues in neonates relative to adult recipients, which may underscore the difference observed 
in long-term engraftment. We also assayed the homing of VE-Cadherin+ CD45+ cells from E11.5 AGM but 
were unable to detect any donor cells at 15 hours post-transplant.  This suggests few early embryonic 
HSCs survive 15 hours post-transplants, and those that survive to contribute to reconstitution are too 
few to detect.  
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Figure 2-6 
 
Figure 2-6: Cycling adult LT-HSCs engraft neonates.  A) FACS plots for Ki-67 and DAPI expression on E14.5 
fetal liver LT-HSCs and sorted bone marrow LT-HSCs from IFNα treated, 5-FU treated, or PBS control  
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Figure 2-6 (Continued) 
adult mice.  B) Neonatal and adult recipients were transplanted with 100 bone marrow LT-HSCs from 
adult mice treated with IFNα (squares) or PBS (circles).  Data shown are at 18 weeks post-
transplantation.  Fisher’s exact test p-value = 0.5581.  C) Neonatal and adult recipients were 
transplanted with 100 bone marrow LT-HSCs from adult mice treated with 5-FU (squares) or PBS 
(circles).  Data shown are at 14 weeks post-transplantation.   
 
Figure 2-7 
 
Figure 2-7: Homing of adult LT-HSCs differs in adult and neonatal recipients.  Percentages of GFP+ 
CD45.2+ donor adult bone marrow LT-HSCs detected in six tissues in adult and neonatal recipients 15 
hours post-transplantation.  Data shown is the mean ± SEM, representing a total of 5 – 6 mice per 
condition with data collected in experimental duplicate for adults and triplicate for neonates.  Liver and 
spleen p-value < 0.05; lung, bone marrow (BM), thymus, and peripheral blood (PB) p-value > 0.05 as 
calculated by the student’s t-test.  
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2.4 Discussion 
 
Although prior literature suggests that the neonate harbors a more permissive environment for 
engraftment of early HSCs [27, 42] and microarray data of early and adult-like HSCs show differentially 
expressed genes with various functional roles [29], there have been no prior reports directly comparing 
and quantifying the repopulating cell frequency of HSCs from multiple points during ontogeny in both 
neonatal and adult recipients.  Here we highlight the importance of the recipient in determination of 
engraftment outcomes, and identify several perplexing differences between the capacity of nascent 
embryonic and definitive adult-like HSCs to engraft either neonates or adults. Specifically, we show that 
nascent embryonic HSCs are better suited to engraftment in neonates; conversely, definitive adult-like 
HSCs, whether harvested from fetal liver or adult bone marrow, more efficiently reconstitute adult 
hosts. We used the neonatal transplant model to better understand the engraftment requirements of 
adult HSCs and identified two factors that may modulate neonatal engraftment potential, differential 
proliferative activity and homing potential. The neonatal transplant assay provides a tool to further our 
understanding of the factors required for survival, maturation, and function of embryonic HSCs and can 
be utilized to functionally examine nascent HSC-like cells derived from pluripotent stem cells.   
Our data are the first to demonstrate robust long-term multi-lineage hematopoietic 
reconstitution of unmanipulated, uncultured E10.5 AGM in wild-type murine recipients, thereby 
establishing that definitive HSCs indeed arise within the embryo at this early stage, but a receptive host 
is required to observe this functionality.  Others have shown that E10.5 AGM and even E9.5 PSp can 
engraft immunodeficient adult recipients, suggesting that genetic immunodeficiency in adult recipients 
enables the same permissiveness to engraftment of embryonic cells as we observe in the neonate [19, 
22, 23, 43, 44].  Indeed, immaturity of the neonatal immune system may represent a reduced 
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transplantation barrier for early embryonic HSCs, which express lower levels of MHC Class I molecules, 
and are thus susceptible to rejection by NK-mediated mechanisms [22].  Interestingly, we have also 
shown that the neonate is not a more permissive recipient for HSCs from all stages of ontogeny, as 
purified LT-HSCs from E14.5 fetal liver and adult bone marrow do not engraft neonates as robustly as 
adults.  Adult-like HSCs likely respond to the neonatal environment differently than early HSCs because 
of the differential expression of genes involved in cytokine-cytokine receptor interaction and membrane 
composition.  The preference of immature HSCs for engraftment in neonates may have clinical parallels 
in the tendency of umbilical cord blood to more robustly engraft juveniles as compared to adults, a 
phenomenon which may not depend entirely on cell dose [45-47].   
Our study suggests that HSC migration to the bone marrow is coupled to limited neonatal 
engraftment potential.  HSCs harvested from the neonatal liver re-engraft in neonates more robustly 
than HSCs harvested from the neonatal bone marrow, indicating that either cell intrinsic changes that 
trigger migration from the liver to the bone marrow also cause decreased neonatal engraftment, or that 
migration to the bone marrow induces an alteration in HSCs that persists as the animal matures, as adult 
bone marrow HSCs yield no or low level engraftment in neonates.  When we surveyed homing of adult 
bone marrow HSCs in neonatal and adult recipients, we found most donor cells in the liver in neonates 
and the liver and spleen in adults. 
Although we detected similar numbers of donor cells in neonates and adults, and a comparable 
percent of donor cells homed to the bone marrow in neonates and adults 15 hours post-injection, long-
term engraftment of adult bone marrow HSCs in neonates was very poor.  Several potential 
explanations can be entertained to account for this. Coupled with our finding that fetal liver HSCs 
engraft neonates more robustly than adult bone marrow HSCs, the evidence suggests that the quiescent 
state of adult HSCs may not be suitable for engraftment in neonatal recipients. The variable engraftment 
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data from adult donor HSCs exposed to IFNα and 5-FU suggest the underlying mechanism maybe more 
complex.  Recent work defines two distinct niches for cycling and quiescent HSCs in adult bone marrow, 
which may be present in different ratios or non-existent in the developing neonatal bone marrow [48].  
Additionally, our neonatal engraftment conditions permit only sub-lethal doses of irradiation, whereas 
engraftment of adults is typically measured after lethal doses of irradiation. The sub-lethal irradiation of 
neonates may not generate a sufficiently strong homeostatic drive to induce substantial proliferation of 
the otherwise quiescent adult HSCs, especially considering the presence of competing actively cycling 
neonatal HSCs.  
In conclusion, we have used the neonatal transplant model to functionally assay the 
engraftment potential of emerging early embryonic HSCs, which go undetected when using wild-type 
adult recipients.  Future studies using the neonatal transplant model may allow us to discover new 
populations in hematopoietic tissues from other points in ontogeny that also engraft neonatal but not 
adult recipients.  Additionally, neonates may provide a unique environment to functionally assay 
hematopoietic derivatives of pluripotent stem cells.   
 
2.5 Materials and Methods 
 
Animals 
C57BL/6 and B6.SJL mice were purchased from Jackson Laboratories and Taconic and bred in 
house. UBC-GFP mice were purchased from Jackson Laboratories (strain #004353) [49].  Experiments 
were carried out with IACUC approval from CHB. 
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Bone Marrow Preparations 
Femurs and tibias from neonatal and adult mice were isolated then crushed with mortar and 
pestle in PBS and strained through a 70 um filter.  The sample was incubated with red blood cell lysis 
buffer on ice for 20-30 minutes then resuspended in PBS for transplantation or PBS with 2% serum for 
flow cytometry. 
Embryonic Tissue Preparations 
Embryonic day was determined by counting the day of vaginal plugging as 0.5 days post coitus.  
Staging of embryos was performed by somite counting. Embryos were collected from timed-mated 
females at E9.5 (16-26 somites), E10.5 (30-39 somites), E11.5 (40-48 somites), and E14.5 (53-55 
somites).  The AGM/PSp was dissected, dissociated with collagenase/dispase (1mg/mL in DMEM) for 30-
60 minutes at room temperature, and strained through a 70 um filter.  The fetal and neonatal liver was 
dissected and mashed over a 70 um filter.  The sample was incubated with red blood cell lysis buffer on 
ice for 20-30 minutes.  Cells were resuspended in PBS for transplantation or PBS with 2% serum for cell 
sorting. 
Bone Marrow Transplantation 
Donor and recipient cells were distinguished by CD45.1 and CD45.2.  Adult recipients were 
either conditioned with a lethal dose of irradiation, 10 Gy total split by 3 hours, and received 3 x 105 cells 
from whole bone marrow as helper or sub-lethally conditioned with a 3.5 Gy or 6.5 Gy dose of 
irradiation and did not receive helper cells.   Donor cells were injected via the tail vein.  Neonatal 
recipients, 1 – 2 days old, were conditioned with a sub-lethal single dose of irradiation, 3.5 Gy, and 
received no helper cells.  Donor cells were injected via the facial vein.  Post-transplantation, mice were 
kept on antibiotic-treated drinking water.  Engraftment was monitored in adult recipients starting 4 
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weeks post-transplant and in neonatal recipients starting 6 weeks post-transplant.  Neonatal recipient 
analysis was delayed due to runted size as a result of irradiation.  Continued engraftment was monitored 
every 4 weeks by flow cytometric analysis of peripheral blood.    
Secondary Transplantations 
Adult secondary recipients were lethally conditioned with a split dose of irradiation, 10 Gy total 
dose split by 3 hours.  One million to 5 million whole bone marrow cells from the primary recipient were 
injected via the tail vein into each of 3 to 4 secondary recipients.   
Peripheral Blood Isolation 
Peripheral blood samples were collected by retro-orbital bleeds with heparinized capillary tubes.  
The red blood cells were allowed to settle out of suspension in PBS with 1% dextran and 0.25M EDTA at 
room temperature.  The buffy layer was pelleted and resuspended in red blood cell lysis buffer on ice for 
20-30 minutes to remove lingering red blood cells.  The remaining leukocyte enriched samples were 
prepared for flow cytometry. 
FACS Analysis and Sorting 
Multicolor FACS analysis was carried out on a 5-laser-LSRII or LSRFortessa flow cytometer 
(Beckton-Dickinson), and sorting was performed on a FACS-Aria+UV (Beckton-Dickinson).  Leukocyte 
enriched peripheral blood cells were stained on ice for 15-30 minutes with the following antibody 
cocktail for lineage analysis: CD45.1 – FITC, CD45.2 – PE/Cy7, Ter119 – PE/Cy5, Gr1 – PE, Mac1 – 
Alexa700, B220 – Pacific Blue, CD19 – APC/Cy7, CD3 – APC, and propidium iodide (Figure 2-8) and for 
homing: CD45.1 – PE and CD45.2 – PE/Cy7. The cells were washed and resuspended in PBS with 2% 
serum.   
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Figure 2-8 
 
Figure 2-8: Analysis of peripheral blood chimerism.  After gating on the live leukocytes, percent donor 
chimerism was determined by analysis of CD45.2 versus CD45.1.  The donor cells were then analyzed for 
lineage contribution, first Mac-1 versus Gr-1 followed by B220 versus CD3 and B220 versus CD19 within 
the Mac-1- Gr-1- quadrant. 
 
To assay the proliferative state of HSCs, isolated HSCs were fixed and permeabilized using the 
BD Cytofix/Cytoperm kit according to the manufacturer’s protocol.  DAPI was used as a nuclear stain and 
Ki-67 – FITC marked proliferating cells.  The cells were washed and resuspended in PBS with 2% serum.   
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To isolate HSCs from bone marrow, samples were stained with biotinylated antibodies against 
Mac1, Gr-1, B220, CD3, and Ter-119, then lineage depleted with anti-biotin MACS beads.  The remaining 
cells were stained with the following antibody cocktail on ice for 15-30 minutes: Lineage (Mac1, Gr1, 
B220, CD3, Ter119) – Alexa450, Sca1 – PerCP-Pc5.5, c-Kit – APC/Cy7, CD150 – PE/Cy7, CD48 – PE, and 
DAPI (Figure 2-9).  Preparations for E14.5 fetal liver were identical to bone marrow except for the use of 
Mac1 in the lineage cocktail.  To isolate prospective HSCs from E11.5 AGM, cells were stained with a 
purified VE-Cadherin antibody followed by a goat anti-rat Alexa680 secondary antibody then CD45 – PE 
and propidium iodide (Figure 2-4 A). 
 
Figure 2-9 
 
Figure 2-9: Isolation of bone marrow LT-HSCs.  After gating on the live lineage negative cells, LSK cells 
were gated on in the c-Kit versus Sca-1 plot.  Within the LSK gate, CD150+ CD48- cells were gated on for 
sorting. 
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Limiting Dilution Analysis (LDA) 
LDA was performed online using software provided by WEHI bioinformatics 
http://bioinf.wehi.edu.au/software/elda/index.html [50].  In all cases, the threshold for engraftment 
was 1% donor chimerism at 18 weeks post-transplantation.   
HSC Proliferation 
To induce HSC proliferation, adult mice were treated with one dose of IFNα (10,000 units given 
subcutaneously) 24 hours prior to HSC isolation.  Alternatively, adult mice received one dose of 5-FU 
(150 mg kg-1) by intraperitoneal injection 5 days prior to HSC isolation. 
Homing 
VE-Cadherin+ CD45+ cells were isolated from E11.5 AGM of UBC-GFP embryos.  LT-HSCs (Lineage- 
Sca-1+ c-Kit+ CD150+ CD48-) were isolated from adult bone marrow of UBC-GFP mice.  Approximately 104 
isolated cells were transplanted into conditioned B6.SJL neonatal and adult recipients.  Transplanting  
purified LT-HSCs in addition to injecting a small number of cells reduces the likelihood of donor cells 
being trapped in the lung.  Adult recipients received 3 x 105 helper cells from B6.SJL bone marrow.  At 15 
hours post-injection, the lung, peripheral blood, bone marrow from the long bones of the leg, spleen, 
liver, and thymus were collected.  Peripheral blood and bone marrow from adult recipients were 
subjected to red blood cell lysis for 20-30 minutes on ice.  Solid tissues were mashed over a 70 um filter.  
Cells from the collected tissues were stained with antibodies for CD45.1 and CD45.2.  Donor cells were 
detected using two markers: CD45.2 and GFP expression.   
Statistical Analysis 
 Fisher exact test was used for statistical analysis of the difference in frequency of engraftment.  
In cases where a majority of the animals were engrafted, the student’s t-test was used for statistical 
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analysis of the engraftment levels.  The LDA algorithm performed statistical analysis on the limiting 
dilution transplants. 
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Chapter 3 
Primitive Fate of RBCs Derived from Human Pluripotent Stem Cells  
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3.1 Abstract 
 
Human pluripotent stem cell (hPSC) derivatives have the potential to provide new sources of 
cells for treatment of hemoglobinopathies and sickle cell disease as well as provide platforms for drug 
screening and in vitro modeling, though the hurdle of generating definitive adult-like red blood cells 
(RBCs) must first be overcome.  Current directed differentiation methods produced only primitive RBCs.  
We compared the directed differentiation of 11 different hPSC lines into RBCs using three different 
published protocols and optimized the most robust and reproducible cell line/protocol combination.  
We then altered the differentiation protocol to include over-expression of key erythroid transcription 
factors, BCL11A and KLF1, and co-culture on stromal cells, but we observed no change in cell fate and 
produced only primitive RBCs.  We also transplanted early progenitors into a supportive in vivo 
environment, but we were unable to detect donor erythroid cells.  The system we have optimized is a 
good platform for larger scale screens of other transcription factors, stromal lines, or chemicals that may 
promote and support the definitive cell fate. 
 
3.2 Introduction 
 
Since the first demonstration of mutant hemoglobin over a half century ago, hundreds of 
mutations in the α- and β-globin loci have been identified.  Many mutations are silent or do not present 
a clinical phenotype, but a few cause severe phenotypes.  One of the most common 
hemoglobinopathies caused by these mutations is sickle cell anemia (SCA).  SCA is caused by a point 
mutation in the sixth codon of the β-globin gene, which predisposes hemoglobin to polymerization, 
52 
 
inducing rigidity and structural deformations of RBCs recognized by a characteristic sickling [1, 2].  
Sickled RBCs cause vaso-occlusion, which leads to painful crises, organ damage, and premature death [3-
8]. 
Current treatments for SCA are limited.  Hydroxyurea reduces the frequency of painful crises by 
lowering white blood cell counts, thereby reducing cellular sludging, and increasing production of γ-
globin which reduces RBC sickling [9, 10].  RBC transfusions temporarily increase the number of 
circulating normal RBCs, but frequent RBC transfusions result in sickle antibody sensitization and iron 
accumulation, which itself causes organ damage [11-17]. Bone marrow transplants are a curative option 
but are riskier than RBC transfusions, given the potential for graft failure, immunologic complications 
like graft-versus-host disease, and considerable risk of morbidity and mortality.  
The advent of induced pluripotent stem cell (iPSC) technology gives hope for patient specific 
RBCs and hematopoietic stem cells that would bypass immunologic complications.  Although iPSCs are 
remarkably similar to embryonic stem cells (ESCs) in pluripotent function, many studies have identified 
subtle but potentially significant molecular differences and differences in the potential to differentiate 
into blood [18-21].  Examination of the blood differentiation potential of 22 hPSC lines generated at 
multiple institutions showed higher hematopoietic colony forming unit activity and better erythroid 
differentiation efficiency from hESCs than hiPSCs [22].  Here, we focused on hPSCs directly differentiated 
into RBCs to improve our understanding of erythropoiesis, provide new therapeutic options for 
hemoglobinopathies, and create a platform to screen anti-sickling compounds.   
The largest hurdle in harnessing the power of PSCs derived RBCs is generating definitive RBCs 
instead of the readily generated primitive RBCs [23-31].  Generating definitive RBCs is necessary for 
disease modeling and drug screening because hemoglobinopathies and SCA do not manifest in primitive 
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RBCs [32, 33].  For cell therapies, it is unknown how patients would respond to treatment with primitive 
cells and how effective primitive cells would be in alleviating symptoms of the disease [34, 35]. 
Definitive RBCs have many unique features that distinguish them from primitive RBCs, but only a 
few are well studied and easy to assay.  Primitive RBCs may not enucleate, are larger in diameter, and 
express ε-globin [36].  Definitive RBCs are enucleated and approximately 6-8 µm in diameter [37].  The 
earliest definitive RBCs express γ-globin while β-globin is expressed in the adult definitive RBCs [36].  
While the expression of different hemoglobin genes is not causative of a change in cell fate, we use it 
here as a marker of the primitive and definitive states.  It has not yet been shown if the type of 
hemoglobin expressed can be uncoupled from the cell fate.    
 Several γ-globin repressors have been identified in mouse studies, GATA-1, OCT-1, and BCL11A, 
that may promote globin switching by reducing competition between γ-globin and β-globin for the locus 
control region [38-45].  Genome wide association studies found BCL11A and KLF1 to be associated with 
hereditary persistence of fetal hemoglobin [38-40, 46].  Further work suggested a direct role of BCL11A, 
specifically the L and XL isoforms, in repressing γ-globin [47, 48].  BCL11A is activated by KLF1, which 
itself activates β-globin [46, 49, 50]. 
 We tested the hypothesis that hPSC derived RBCs could transition from the primitive to 
definitive fate, and we found the cell fate of hPSC derived RBCs to be unaltered by a variety of 
approaches.  There are two possible explanations: 1) the precursor of primitive RBCs cannot be 
converted into a definitive RBC precursor under tested conditions or 2) the precursors that give rise to 
definitive RBCs cannot emerge under standard tissue culture conditions. 
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3.3 Results 
 
We tested three published protocols for directed differentiation of hPSCs into RBCs with 10 
hiPSC lines and 1 hESC line originating from a variety of somatic cell types including fibroblasts, cord 
blood, and mesenchymal stem cells (Figure 3-1) [25, 29, 30].  We examined the general hematopoietic 
differentiation potential of each line by the ability to form CFUs, the diameter of the hPSC derived RBCs, 
the capacity for expansion during differentiation, and the amount of hemoglobin mRNA present (Table 
3-1).  Regardless of the hPSC line or protocol used, the resulting RBCs were primitive.  With some 
modifications, the main protocol from Lu et al. generated large numbers of RBCs through a 
hemangioblast expansion phase followed by erythroid differentiation and expansion.  We found 
recombinant HoxB4 was unnecessary for both directed differentiation and generation of large numbers 
of RBCs.  At the end of the differentiation, many of the hPSC lines made RBCs but not to the same 
degree in terms of the maturity and number of RBCs produced (Figure 3-2).  MSC-iPS1, a mesenchymal 
stem cell derived hiPSC line, was the most robust of all tested hPSC lines and therefore was used for all 
other studies.  
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Figure 3-1 
 
Figure 3-1: hPSC differentiation protocols.  Schematic representation of the Chang protocol (top), Ma 
protocol (middle), and Lanza protocol (bottom).  Modified from Lu et al., Chang et al., and Ma et al. 
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Table 3-1: Comparison of hematopoietic differentiation of multiple hPSC lines.  The CFU column displays 
the types of colonies formed from each hPSC line.  The cell diameter (size) was determined from 
derivatives of the Chang protocol.  Expansion was calculated as output cells/input cells.  Hemoglobin 
expression was determined by qPCR for ε-, γ-, and β-globin.   
 
 
Figure 3-2 
 
Figure 3-2: Expression of erythroid markers.  FACS analysis of erythroid markers CD71 and GPA on cells 
from the Lanza protocol originating from 5 hPSC lines.   
 
Cell 
Line 
CFU 
Size (µm) 
after Chang 
Expansion 
in Chang 
Expansion 
in Ma 
Expansion 
in Lanza 
Hemoglobin 
Expression 
H1 E, M, GM 21-25 N/D 7-fold 2.97-fold Inconsistent 
hFib2-
iPS5 
Almost 
none, M, G 
N/D N/D N/D 0.38-fold Almost none 
MRC5-
iPS20 
M, G, GM, 
GEMM 
22 N/D N/D 0.03-fold Moderate 
MSC-
iPS1 
M,G, GM 28 2.9-fold N/D 0.65-fold Weak 
MRC5-
iPS7 
M, G, GM 20 2.75-fold N/D 0.1-fold Moderate 
BJ1-
iPS2 
N/D N/D 2.5-fold N/D N/D Moderate 
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We further characterized the hPSC derived RBCs.  RBCs arose in colonies sometimes during the 
hemangioblast expansion phase but more often during the erythroid specification phase (Figure 3-3 A).  
At the end of the protocol, the cultures consisted mostly of nucleated orthochromatic erythroblasts and 
macrophages (Figure3- 3 B).  Likely due to the retention of the nucleus, the average diameter of the 
hPSC derived RBCs was 17.6 µm, which is larger than in vivo RBCs (Figure 3-3 C).  FACS analysis of RBC 
surface antigens CD71 and GPA showed maturation of hPSC derived RBCs (Figure 3-3 D).  As expected 
from the data in Lu et al., the RBCs derived from multiple hPSC lines expressed embryonic (ε) and fetal 
(γ) hemoglobins but not the adult β-globin when both bulk cultures and single cells were analyzed 
(Figure 3-3 E and F).  Cord blood controls expressed both γ-globin and β-globin, but no ε-globin (Figure 
3-3 E and G).  Closer analysis of hemoglobin expression at the single cell level showed a gradient of ε/γ 
expression (Figure 3-3 F).  Examination of hemoglobin expression during the hemangioblast expansion 
phase showed that the ratio of expressed hemoglobins is established early during differentiation (Figure 
3-4).  In addition to hemoglobin expression, we also used Ep1 to assess the developmental stage of hPSC 
derived RBCs [51].  Stamatoyannopoulos’s group reported Ep1 expression was more prevalent on fetal 
RBCs than adult RBCs.  Less than 1% of cord blood cells expressed Ep1, whereas 3.5% of hPSC derived 
RBCs expressed Ep1, suggesting cord blood and hPSC derived RBCs could be of similar developmental 
stages even though they express different hemoglobins (Figure 3-5).  We confirmed the Ep1+ cells were 
erythroblasts by CD71 and GPA expression.   
In light of many papers demonstrating plasticity of cell fate and the power of key transcription 
factors to alter cell fate [52-55], we analyzed the expression of a panel of erythroid transcription factors 
and tested the potency of two key factors, BCL11A and KLF1.  The ratio of expressed hemoglobins was 
used as an indicator of primitive versus definitive cell fate.  During the early stages of directed 
differentiation, we found no clear patterns in the mRNA levels of erythroid transcription factors, 
suggesting a loosely regulated or stochastic process (Figure 3-6).  
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Figure 3-3 
 
Figure 3-3: Primitive hPSC derived RBCs from Lanza protocol.  A) Bright-field image of RBC clusters 
during the erythroid differentiation phase.  B) Wright-Giemsa staining on cytospins from the erythroid 
differentiation phase show orthochromatic erythroblasts.  C) Diameter of cells derived from two hiPSC 
lines at the end of the erythroid differentiation phase.  D) FACS analysis of differentiating cells.  E) 
Hemoglobin expression in derivatives of 4 hiPSC lines at the end of the differentiation protocol.  
Expression was determined by qPCR and compared to cord blood mononuclear cells (CBMC).  F) Single- 
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Figure 3-3 (Continued) 
cell qPCR analyzing hemoglobin expression in MSC-iPS1 derived RBCs at the end of the differentiation 
protocol.  G) Single cell qPCR analyzing hemoglobin in CD71 enriched cord blood. 
 
Figure 3-4 
 
Figure 3-4: Hemoglobin expression during hemangioblast expansion.  A time course analysis of the 
hemoglobins expressed, as determined by qPCR, during the hemangioblast expansion phase with MSC-
iPS1 cells.  Expression is compared to CD71 enriched cord blood mononuclear cells (CB CD71+).   
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Figure 3-5 
 
Figure 3-5: Expression of developmental marker Ep1.  FACS analysis of Ep1 on cord blood cells compared 
to RBCs derived from three hPSC lines and subsequent analysis of CD71 and GPA within the Ep1+ gate.  
CB – cord blood. 
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Figure 3-6 
 
Figure 3-6: Erythroid transcription factors during differentiation.  mRNA levels of erythroid transcription 
factors at the end of the embryoid body phase (EB D3.5) and at time points during the hemangioblast 
expansion phase determined by qPCR.  
 
We developed a method to introduce exogenous transcription factors at the beginning of the 
hemangioblast expansion phase (Figure 3-7 A).  We hypothesized that exogenous transcription factors 
would need to be expressed early during differentiation to alter the hemoglobin expression patter that 
seemed to be established in the hemangioblasts.  GFP+ cells expressing CD71 and GPA demonstrate that 
the exogenous factors were expressed in the hPSC derived RBCs (Figure 3-7 B).  Increasing expression of 
two known key erythroid transcription factors BCL11A and KLF1 by 1.7- to 7.5-fold highlighted 
interesting relationships between the two factors (Figure 3-7 C).  We examined the effect of over-
expressing BCL11A-L and BCL11A-XL as both isoforms are expressed in definitive RBCS [47, 48].  KLF1 
levels dropped 6.3-fold when BCL11A-L was over-expressed and dropped 12.5-fold when BCL11A-XL was 
over-expressed, suggesting a negative feedback loop as KLF1 is known to activate BCL11A.  BCL11A-XL 
seems to be a more potent repressor of KLF1 than BCL11A-L.  The ratio of expressed hemoglobins in the 
bulk culture was largely unaltered by the over-expression of KLF1, BCL11A-L, or BCL11A-XL (Figure 3-7 
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D).  Single cell analysis showed no change in hemoglobin expression after KLF1 over-expression (Figure 
3-7 F).  However, over-expression of KLF1 along with BCL11A-L produced 1 cell out of the 44 examined 
with 94% β-globin (Figure 3-7 G); as this was not seen in controls, it indicates that KLF1 and BCL11A-L 
may activate β-globin expression and repress γ-globin expression during differentiation of hPSCs, but it 
is a rare event.   
One possible explanation for the observed lack of change in hemoglobin expression is that the 
proper microenvironment providing cell-cell interactions and additional growth factors are missing [56-
58].  To test this hypothesis, we cultured differentiating cells on human fetal liver and bone marrow 
stromal lines.  There was no detectable difference in hemoglobin expression after 13-15 days of co-
culture, suggesting that the cells were not responsive to the added microenvironment or that the 
stromal lines did not provide the cell-cell interactions and growth factors necessary to convert the cells 
to the definitive fate (Figure 3-8).  
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Figure 3-7
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Figure 3-7 (Continued) 
 
Figure 3-7: Over-expression of key erythroid transcription factors.  A) Bright-field and fluorescent image 
of differentiating MSC-iPS1 infected with a GFP virus.  B) FACS analysis of GFP+ cells also expressing CD71 
and GPA.  C) Expression of key erythroid transcription factors after over-expression with exogenous KLF1 
and/or BCL11A determined by qPCR.  D)  Expression of hemoglobins after over-expression of KLF1 
and/or BCL11A determined by qPCR.  CB – cord blood.  Single cell qPCR analysis of expression of 
hemoglobin genes in differentiating cells infected with E) control virus, E) KLF1 virus, or G) KLF1 and 
BCL11A-L virus. 
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Figure 3-8 
 
Figure 3-8: Co-culture during differentiation.  Hemoglobin expression of differentiating MSC-iPS1 cells 
co-cultured on bone marrow (BM) or fetal liver (FL) stromal cells.  No stroma – differentiating cells 
without any co-culture.  qPCR was used to determine expression of each hemoglobin, which was 
normalized to expression in cord blood cells enriched for CD71 expression.   
    
We next determined if hematopoietic stem/progenitor cells derived from hiPSCs by the 
modified Lu et al. protocol have the potential to generate definitive RBCs in the hypothesized most 
permissive environment, immunodeficient neonates engineered to express human SCF, GM-CSF, and IL-
3.  First, we assessed the potential for and function of hematopoietic stem/progenitor cells.  FACS 
analysis showed the number of CD34+ CD38- cells peaked at day 7 of the hemangioblast expansion phase 
(Figure 3-9 A).  CFU analysis on bulk differentiation cultures showed more colonies forming on or before 
day 6 of the hemangioblast expansion phase with a small number of GEMM colonies present at all days 
analyzed (Figure 3-9 B).  These data suggest the presence of hematopoietic stem/progenitor cells 
between days 4 – 8 of the hemangioblast expansion phase.  We transplanted 1-2 x 106 cells from day 6 
and day 8 of the hemangioblast expansion phase into each of 36 NSG or NSG-SGM3 neonatal recipients 
via intrahepatic or intravenous injection and compared engraftment to 50,000 CD34+ enriched cord 
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blood cells.  We used two different antibody clones for CD45 to confidently identify low level human 
chimerism.  At 6 months post-transplant, the cord blood cells had engrafted the mice, but we detected 
no consistent or robust donor chimerism as early as 2 weeks or as late as 6 weeks weeks/months post-
transplant in mice that received hPSC derivatives (Figure3-10).  There are many possible explanations for 
the lack of donor chimerism.  Coupled with the CFU analysis, we suspect short-term survival of the 
donor cells is low, thus we cannot detect the presence of donor cells or their progeny even at 2 weeks 
post-transplant.  
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Figure 3-9 
 
Figure 3-9: Emergence of hematopoietic stem/progenitor cells. A) Percent  of hemangioblast expansion 
culture that is CD34+ CD38- as determined by FACS analysis at different time points. B) Hematopoietic 
colony forming potential of cells during the hemangioblast expansion phase.   
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Figure 3-10 
 
Figure 3-10: Neonatal xenotransplantation.  Cord blood CD34+ cells and hPSC derivatives from the 
hemangioblast expansion phase were transplanted into neonatal NSG mice.  FACS analysis shows the 
percent donor chimerism in the bone marrow after 2 weeks.  CB – cord blood 
 
3.4 Discussion 
 
Our data is suggestive of a hypothesis where embryonic and definitive RBCs stem from two 
distinct stem/progenitor populations that have limited plasticity [36, 37].  In comparing three previously 
published protocols for the directed differentiation of hPSCs towards RBCs, we confirmed the hPSC 
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derived RBCs to be primitive in all protocols, regardless of the hPSC line the RBCs were derived from.  
Using the Lanza protocol, which was the only one that generated large numbers of RBCs, we were 
unable to alter RBC fate, measured by the ratio of expressed hemoglobins, by over-expressing key 
erythroid transcription factors, co-culturing on stromal lines, and transplanting derived cells into a 
hypothesized supportive in vivo environment. 
As expected from the literature, RBCs generated through the Lanza protocol were primitive, 
expressing similar amounts of ε-globin and γ-globin but negligible amounts of β-globin.  By FACS, we 
observed the cells maturing through erythropoiesis, from CD71+ GPA+ to CD71
- GPA+.   At the end of the 
differentiation protocol, the cells were still nucleated, which is related to the observed large cell 
diameter.  This phenotype was consistent regardless of the original hPSC line used.  iPSCs have a bias 
towards differentiating into the lineage of the starting somatic tissue by retaining cellular memory after 
reprogramming [19].  We directly differentiated two cord blood derived hiPSC lines into RBCs, but the 
hemoglobin expression pattern was nearly identical to that of all other tested hiPSC lines, suggesting the 
cells retain no memory of their definitive state before reprogramming.  Similar resetting of ageing genes 
has been reported in the context of iPSCs generated with samples from Parkinson’s patients [59]. 
Our strategy to alter the fate of the hPSC derived RBCs was to provide new signals early during 
differentiation while the cells were still in the reported hemangioblast phase.  We hypothesized that the 
cells would be less responsive to fate change cues once they committed to the erythroid lineage.  Over-
expressing key erythroid transcription factors, BCL11A and KLF1, that are known to be involved in 
hemoglobin regulation did not consistently or robustly affect the ratio of expressed hemoglobins [46, 
47, 49].  It is possible that additional factors such as Sox6 and c-Myb are required to alter the fate of 
embryonic RBCs [38, 60-63].  The system we developed for viral infection during directed RBC 
differentiation can be used to screen other key transcription factors, co-factors, and epigenetic 
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regulators that will come out of future analysis of published microarrays [64-66].  However, determining 
which transcription factors to screen may require preliminary studies as our data shows inconsistent 
expression of key erythroid transcription factors in the early phases of directed differentiation. 
Stromal lines have been shown to enhance the derivation and maintenance of many cell types 
including hPSCs and hematopoietic stem cells [67-70].  We observed no change in the ratio of expressed 
hemoglobins when we cultured differentiating cells on hematopoietic supportive human fetal liver or 
bone marrow stromal lines previously reported to support hematopoietic cells [68, 71].  With recently 
available microarray data [64, 66], cell-cell interactions and cytokine receptors that differ between 
embryonic and definitive RBCs and their progenitors could identify stromal lines with supportive of the 
emergence of definitive RBCs.  
In an effort to provide the most supportive environment for the emergence of definitive RBCs, 
we transplanted a bulk mixed culture of hPSC derived hemangioblasts and RBC progenitors 
intrahepatically into neonatal immunodeficient mice expressing human SCF, GM-SCF, and IL-3, but we 
did not detect consistent or robust engraftment.  By introducing the cells intrahepatically, we removed 
the possibility that the cells were unable to home to a hematopoietic tissue.  There are many other 
factors that may have contributed to our observations.  Human erythroid engraftment is known to be 
short-lived, and thus donor erythroid cells may be depleted by 2 weeks post-transplant.  Also, the 
embryonic cells may not survive in the host animal [72, 73]. 
Collectively, our data supports the hypothesis that the embryonic and definitive erythroid 
lineages arise from two different stem/progenitor populations.  Further work is needed to understand 
the plasticity of the two populations.  The two stem/progenitor populations could be extremely plastic.  
Culture conditions supportive of the embryonic state may hinder the emergence of extremely plastic 
definitive stem/progenitor cells, as the definitive cell would rapidly convert to the embryonic fate.  
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Alternatively, the two stem/progenitor populations may have minimal plasticity, thereby 
restricting direct conversion or maturation in an environment that supports the emergence of 
embryonic cells.  Stem cell biologists have yet to find the key to mature cells to the definitive fate, as it is 
easier to return a cell to a state it passed through during development than it is to restrict a 
differentiating cell to a specific fate that it has no cellular memory of.  Adult cells are able to return to a 
more embryonic state as exemplified by iPSC reprogramming and increased fetal hemoglobin in RBCs 
after BCL11A knockdown [47, 55, 74].  Although, it is unknown if the fate of the cells, or only the 
hemoglobin expression, was altered.   
 Once the technology exists to create definitive RBCs, it can be coupled with SCA-iPSC lines to 
produce an in vitro model of SCA.  Three groups have reported the generation of humanized iPSC 
models of SCA [75-77].  Only one report demonstrated sickling of hiPSC derived RBCs [77].  Other groups 
used zinc finger nucleases and CRISPR to create genetically corrected SCA-iPSC lines, which can be 
utilized as controls in screens for anti-sickling compounds [76, 78].  The technology would also enable 
the production of genetically corrected patient specific hiPSC derived RBCs for patients with no 
histocompatible donor.   
 
3.5 Materials and Methods   
 
hPSC Maintenance 
hPSCs were maintained on mouse embryonic fibroblasts (MEFs) in hES medium (DMEM-F12 
supplemented with 20% knock-out serum replacement,  100 µM nonessential amino acids, 50 U/mL 
penicillin, 50 mg/mL streptomycin, 1 mM L-glutamine, 100 µM 2-mercaptoethanol, and 10 ng/mL bFGF). 
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Before plating MEFs, tissue culture plates were pre-coated with 2% gelatin for 20 minutes at room 
temperature.  MEFs (Global Stem CF-1 irradiated) were quickly thawed at 37C, centrifuged at 1,200 rpm 
for 4 minutes, resuspended, and plated in MEF medium (DMEM supplemented with 10% fetal calf 
serum, 50 U/mL penicillin, 50 mg/mL streptomycin, and 1 mM L-glutamine) at a density of 67,000 MEFs 
per well of a 6-well plate.  MEF plates rested for 12 – 48 hours before hPSCs were plated on top.   
hPSCs were passaged every 5 days to maintain cultures with less differentiation.  Differentiation 
was first aspirated away, and then media was replaced with collagenase IV (1 mg/mL in DMEM-F12).  
After 5 minutes, the enzymatic solution was replaced with DMEM-F12.  Adherent colonies were scraped 
from the plate using a cell lifter, collected in a conical tube, and spun down at 1,000 rpm for 2 minutes.  
hPSC colonies were gently resuspended in hES media and plated on MEFs.  The freshly passaged 
colonies were left untouched for one day before daily media changes resumed.  
RBC Differentiation methods 
hPSCs were directly differentiated into RBCs using three previously published protocols.  The 
first method (Chang) differentiated hPSCs as embryoid bodies (EBs) for 14 days and then plated whole 
EBs on a matrigel membrane with hematopoietic cytokines to induce directed differentiation.  It took 27 
– 42 days to generate RBCs.  Full details of the Chang differentiation method have been published [25].  
The second method (Ma) differentiated whole hPSC colonies on murine fetal liver stromal cells for 15 
days then transferred the cells to colony cultures and subsequently suspension cultures with 
hematopoietic cytokines for an additional 20 days to generate RBCs.  Full details of the Ma 
differentiation method have been published [30].  The third method (Lanza) is more defined and serum-
free.  hPSCs were differentiated as EBs for 3.5 days then dissociated to single cells and plated in a 
methylcellulose based media with hematopoietic cytokines to promote hemangioblast expansion 
followed by erythroid differentiation and expansion.  RBCs are generated after 21 days.  The details of 
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the Lanza method have been published [29, 79], but we made the following 3 modifications for 
optimization. 1) hPSCs were passaged as described above.  Passage with trypsin, as described in Lu et al., 
led to loss of pluripotency. 2) EBs were dissociated with 0.25% trypsin for 2 minutes, flicking the tube 
every 30 seconds. After 2 minutes, EBs were triturated with a P1000 and passed through a 40 µm 
strainer into a 50 mL conical tube, which was then filled with PBS + 0.1% BSA to dilute the trypsin.  3) No 
recombinant HoxB4 was used during the differentiation, as we achieved consistently high RBC yield 
without exogenous HoxB4.   
Cord Blood Mononuclear Cell (CBMC) Isolation 
Fresh cord blood was obtained from the Pasquarello Tissue Lab with approval from CHB.  The 
cord blood was mixed with 4 volumes of cold PBS + 2 mM EDTA.  Then, 35 mL was layered on top of 15 
mL of Ficoll-Paque in 50 mL conical tubes and centrifuged at 400 x g for 30 minutes at 20°C.  The 
mononuclear cell layer was collected and washed twice with PBS + 2 mM EDTA, centrifuging at 300 x g 
for 30 minutes at 20°C, followed by one last wash and centrifugation at 4°C.   
MACS Enrichment 
CBMCs were enriched for CD34+ cells or CD71+ cells using MACS (Miltenyi).   CBMCs were 
stained with either 1) CD71-APC antibody or 2) CD34-APC antibody followed by anti-APC beads and 
resuspended in PBS + 2% serum, before flowing through an equilibrated LS column.   All staining was for 
15-30 minutes on ice.  Percent enrichment was determined by flow cytometry.  
FACS Analysis 
Multicolor FACS analysis was carried out on a 5-laser-LSRII or LSRFortessa flow cytometer 
(Beckton-Dickinson), and sorting was performed on a FACS-Aria+UV (Beckton-Dickinson).  Cells from the 
hemangioblast expansion phase were stained on ice for 15-30 minutes on ice with antibodies for 
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hematopoietic stem cells markers: CD34 – Pacific Blue, CD38 – PE, and propidium iodide.  The cells were 
washed and resuspended in PBS + 2% serum.  RBCs were stained on ice for 15-30 minutes on ice with 
antibodies to assess erythroid maturation: CD71 – APC, GPA – PE, Ep1 – FITC, and propidium iodide, and 
then either analyzed or sorted.  Ep1 antibody was generously provided by Dr. Stamatoyannopoulos. For 
single cell qPCR, CD71+ GPA+ cells were sorted as single cells into 96-well plates containing 2 µL lysis 
buffer (250 mM Guanidine Thiocyanate) per well.      
To detect hPSC derivatives after transplantation, cells from the collected tissues were stained on 
ice for 15-30 minutes with antibodies for CD45 – PE/Cy5; APC/Cy7 (2 clones were used), CD71 – FITC, 
GPA – PE/Cy7, CD19 – PE, CD33 – APC, and DAPI.  Cells were then washed and resuspended in PBS + 2% 
serum. 
qPCR 
RNA for bulk population qPCR was isolated from samples in Trizol and then reverse transcribed 
using the SuperScript II RT kit (Invitrogen).  The resulting cDNA was used for qPCR with SYBR Green 
master mix and published primers for hemoglobins and erythroid transcription factors (Table 3-2). 
cDNA was synthesized from single cells sorted into lysis buffer in 96-well plates using the SuperScript II 
RT kit reagents adapted for smaller reaction volumes.  The cDNA from each well was then divided 
equally between 3 96-well plates for qPCR of ε-globin, γ-globin, and β-globin using SYBR Green master 
mix. 
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Table 3-2: qPCR primers 
Gene  Primer Sequence Source 
KLF11  forward    GCATGATAGTTTCTTGGGTCAACC [80] 
 reverse      GTAGGCGATGCTATAGTCCACAG  
EpoR  forward    TGGAAGAGGATGGAGGTCGG [81] 
 reverse      GCTGGGAAGAGTTGACCAACAG  
GATA-1  forward    GCCCTGACTTTTCCAGTACC [82] 
 reverse      CGAGTCTGAATACCATCCTTCC  
KLF2  forward    TGCGGCAAGACCTACACCAAGAGT [83] 
 reverse      AGCCGCAGCCGTCCCAGTT  
GATA-4  forward    AGAAAACGGAAGCCCAAGAAC [84] 
 reverse      CTGGAGTTGCTGGAAGCAC  
LMO2  forward    GGCGGCGCCTCTACTACA [85] 
 reverse      CTGGGCCGGAAGCTCTGCC  
SP1  forward    CAGACTCAGTATGTGACCAA [86] 
 reverse      GTTGAGTAGCTATTGGCATT  
SOX6  forward    GAGGCAGTTCTTTACTGTGG [87] 
 reverse      CCGCCATCTGTCTTCATAC  
SCL/Tal1  forward    GTTCTTTGGGGAGCCGGATG [87] 
 reverse      ACATTCTGCTGCCGCCATCG  
STAT5A  forward    TTACTGAAGATCAAGCTGGGG [87] 
 reverse      TCATTGTACAGAATGTGCCGG  
STAT5B  forward    CATTTTCCCATTGAGGTGCG [87] 
 reverse      GGGTGGCCTTAATGTTCTCC  
YY1  forward    AAGGCTGCACAAAGATGTTCA PrimerBank 
 reverse      CATAGGGCCTGTCTCCGGTAT  
FOG1  forward  CTGAAGAAGCCGCCAACTCA [88] 
 reverse      AAGGCGCACATATAGCAGTCC  
IKAROS  forward    CGGCTTTGTCGGGAGTTG [89] 
 reverse      GCCCTTCTGGGTGAATGAG  
hBCL11A  forward    AACCCCAGCACTTAAGCAAA  [61] 
 reverse      GGAGGTCATGATCCCCTTCT  
hKLF1  forward    TTGCGGCAAGAGCTACACC PrimerBank 
 reverse      GTCAGAGCGCGAAAAAGCAC  
hMYB  forward    TACAATGCGTCGGAAGGTCG [90] 
 reverse      GCGGAGCCTGAGCAAAACC  
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CFU Assay 
Cells from the hemangioblast expansion phase were collected with PBS + 0.1% BSA.  Each CFU 
dish contained 25,000 to 50,000 cells mixed with 1.5 mL of MethoCult 4434.  Colonies were counted 
after 14 days. 
Lentiviral Over-Expression of Transcription Factors in Differentiating hPSCs 
 BCL11A-L, BCL11A-XL, and KLF1 (GeneCopoeia) were cloned into lentiviral vectors using the 
Gateway system.  Genes of interest were first recombined into pENTR, then shuttled to either pSMAL or 
pLenti.  The GFP control plasmids were purchased directly (GeneCopoeia). 293T cells were transfected 
with plasmids for the genes of interest along with third-generation packaging plasmids.  Virus was 
harvested 24 hours after transfection and concentrated by ultracentrifugation at 22,000 rpm for 
2.3 hours.   Viral titers were determined by serial dilution on 293T cells. 
During the entire viral infection process, hPSC derivatives were kept in media similar to that of 
step 2 media from the Lanza protocol, except that StemLine I media replaced the methylcellulose.  After 
EB dissociation, cells were infected with concentrated virus (10 MOI) by centrifuging the cells with virus 
and protamine sulfate for 30 minutes at 2,000 rpm.  The virus was left on the cells for 24 hours, then 
washed off with PBS + 0.1% BSA.  Cells were plated in regular step 2 media containing methylcellulose 
and differentiation continued as previously described.  The efficiency of viral infection was determined 
by flow cytometry after 72 -  96 hours.  
Co-culture During Differentiation 
Dissociated EBs in normal step 2 media were seeded on top of 70,000 human bone marrow (HS-
5) and fetal liver (FL62891) stromal lines (ATCC).  The differentiating cells remained in co-culture for the 
remainder of the differentiation.   
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Animals 
NSG and NSG-SGM3 mice were purchased from Jackson Laboratories and bred in house (strains 
005557 and 013062). Experiments were carried out with IACUC approval from CHB. 
Transplantation Assay 
NSG and NSG-SGM3 neonates, 1-2 days old, were conditioned with 100 rads of radiation.  
Neonates received 1x106 cells from day 6 or day 8 of step 2 resuspended in PBS + 0.1% BSA and injected 
either intravenously in 15 µL or intrahepatically in 50 µL.  Recipients were euthanized at 2, 4, or 6 weeks 
post-transplant for collection of the thymus, spleen, liver, lung, bone marrow, and peripheral blood.  
Peripheral blood and bone marrow were subjected to red blood cell lysis for 20-30 minutes on ice.  Solid 
tissues were mashed over a 70 um filter for flow cytometry.   
 
3.6 References 
 
1. Ingram, V.M., A specific chemical difference between the globins of normal human and sickle-cell 
anaemia haemoglobin. Nature, 1956. 178(4537): p. 792-4. 
2. Ingram, V.M., Gene mutations in human haemoglobin: the chemical difference between normal 
and sickle cell haemoglobin. Nature, 1957. 180(4581): p. 326-8. 
3. Brittenham, G.M., A.N. Schechter, and C.T. Noguchi, Hemoglobin S polymerization: primary 
determinant of the hemolytic and clinical severity of the sickling syndromes. Blood, 1985. 65(1): 
p. 183-9. 
4. Crepeau, R.H., et al., Diameter of haemoglobin S fibres in sickled cells. Nature, 1978. 274(5671): 
p. 616-7. 
5. Dykes, G.W., R.H. Crepeau, and S.J. Edelstein, Three-dimensional reconstruction of the 14-
filament fibers of hemoglobin S. J Mol Biol, 1979. 130(4): p. 451-72. 
78 
 
6. Eaton, W.A. and J. Hofrichter, Hemoglobin S gelation and sickle cell disease. Blood, 1987. 70(5): 
p. 1245-66. 
7. Hofrichter, J., P.D. Ross, and W.A. Eaton, Kinetics and mechanism of deoxyhemoglobin S 
gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci U S A, 1974. 
71(12): p. 4864-8. 
8. Noguchi, C.T. and A.N. Schechter, The intracellular polymerization of sickle hemoglobin and its 
relevance to sickle cell disease. Blood, 1981. 58(6): p. 1057-68. 
9. Letvin, N.L., et al., Augmentation of fetal-hemoglobin production in anemic monkeys by 
hydroxyurea. N Engl J Med, 1984. 310(14): p. 869-73. 
10. Platt, O.S., et al., Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin 
Invest, 1984. 74(2): p. 652-6. 
11. Coles, S.M., H.G. Klein, and P.V. Holland, Alloimmunization in two multitransfused patient 
populations. Transfusion, 1981. 21(4): p. 462-6. 
12. Cox, J.V., et al., Risk of alloimmunization and delayed hemolytic transfusion reactions in patients 
with sickle cell disease. Arch Intern Med, 1988. 148(11): p. 2485-9. 
13. Davies, S.C., et al., Red cell alloimmunization in sickle cell disease. Br J Haematol, 1986. 63(2): p. 
241-5. 
14. Orlina, A.R., P.J. Unger, and M. Koshy, Post-transfusion alloimmunization in patients with sickle 
cell disease. Am J Hematol, 1978. 5(2): p. 101-6. 
15. Reisner, E.G., et al., Alloantibody responses in multiply transfused sickle cell patients. Tissue 
Antigens, 1987. 30(4): p. 161-6. 
16. Rosse, W.F., et al., Transfusion and alloimmunization in sickle cell disease. The Cooperative Study 
of Sickle Cell Disease. Blood, 1990. 76(7): p. 1431-7. 
17. Vichinsky, E.P., et al., Alloimmunization in sickle cell anemia and transfusion of racially 
unmatched blood. N Engl J Med, 1990. 322(23): p. 1617-21. 
18. International Stem Cell, I., et al., Characterization of human embryonic stem cell lines by the 
International Stem Cell Initiative. Nat Biotechnol, 2007. 25(7): p. 803-16. 
19. Kim, K., et al., Donor cell type can influence the epigenome and differentiation potential of 
human induced pluripotent stem cells. Nat Biotechnol, 2011. 29(12): p. 1117-1119. 
20. Choi, K.D., et al., Hematopoietic and endothelial differentiation of human induced pluripotent 
stem cells. Stem Cells, 2009. 27(3): p. 559-67. 
21. Osafune, K., et al., Marked differences in differentiation propensity among human embryonic 
stem cell lines. Nat Biotechnol, 2008. 26(3): p. 313-5. 
79 
 
22. Feng, Q., et al., Hemangioblastic derivatives from human induced pluripotent stem cells exhibit 
limited expansion and early senescence. Stem Cells, 2010. 28(4): p. 704-12. 
23. Carotta, S., et al., Directed differentiation and mass cultivation of pure erythroid progenitors 
from mouse embryonic stem cells. Blood, 2004. 104(6): p. 1873-80. 
24. Umeda, K., et al., Sequential analysis of alpha- and beta-globin gene expression during 
erythropoietic differentiation from primate embryonic stem cells. Stem Cells, 2006. 24(12): p. 
2627-36. 
25. Chang, K.H., et al., Definitive-like erythroid cells derived from human embryonic stem cells 
coexpress high levels of embryonic and fetal globins with little or no adult globin. Blood, 2006. 
108(5): p. 1515-23. 
26. Olivier, E.N., et al., Large-scale production of embryonic red blood cells from human embryonic 
stem cells. Exp Hematol, 2006. 34(12): p. 1635-42. 
27. Qiu, C., et al., Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells 
produced from human embryonic stem cells. Blood, 2008. 111(4): p. 2400-8. 
28. Hiroyama, T., et al., Establishment of mouse embryonic stem cell-derived erythroid progenitor 
cell lines able to produce functional red blood cells. PLoS One, 2008. 3(2): p. e1544. 
29. Lu, S.J., et al., Biologic properties and enucleation of red blood cells from human embryonic stem 
cells. Blood, 2008. 112(12): p. 4475-84. 
30. Ma, F., et al., Generation of functional erythrocytes from human embryonic stem cell-derived 
definitive hematopoiesis. Proc Natl Acad Sci U S A, 2008. 105(35): p. 13087-92. 
31. Maclean, G.A., et al., Altered hematopoiesis in trisomy 21 as revealed through in vitro 
differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A, 2012. 109(43): p. 
17567-72. 
32. Forget, B.G., Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci, 
1998. 850: p. 38-44. 
33. Thein, S.L. and J.E. Craig, Genetics of Hb F/F cell variance in adults and heterocellular hereditary 
persistence of fetal hemoglobin. Hemoglobin, 1998. 22(5-6): p. 401-14. 
34. Thein, S.L. and S. Menzel, Discovering the genetics underlying foetal haemoglobin production in 
adults. Br J Haematol, 2009. 145(4): p. 455-67. 
35. Thein, S.L., et al., Control of fetal hemoglobin: new insights emerging from genomics and clinical 
implications. Hum Mol Genet, 2009. 18(R2): p. R216-23. 
36. Palis, J., Primitive and definitive erythropoiesis in mammals. Front Physiol, 2014. 5: p. 3. 
37. Dzierzak, E. and S. Philipsen, Erythropoiesis: development and differentiation. Cold Spring Harb 
Perspect Med, 2013. 3(4): p. a011601. 
80 
 
38. Lettre, G., et al., DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate 
with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A, 2008. 
105(33): p. 11869-74. 
39. Menzel, S., et al., A QTL influencing F cell production maps to a gene encoding a zinc-finger 
protein on chromosome 2p15. Nat Genet, 2007. 39(10): p. 1197-9. 
40. Uda, M., et al., Genome-wide association study shows BCL11A associated with persistent fetal 
hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A, 
2008. 105(5): p. 1620-5. 
41. Harju-Baker, S., et al., Silencing of Agamma-globin gene expression during adult definitive 
erythropoiesis mediated by GATA-1-FOG-1-Mi2 complex binding at the -566 GATA site. Mol Cell 
Biol, 2008. 28(10): p. 3101-13. 
42. Stamatoyannopoulos, G. and A.W. Nienhuis, Hemoglobin switching, in The molecular basis of 
blood diseases, G. Stamatoyannopoulos, et al., Editors. 1994, W.B. Saunders Company: 
Philadelphia. p. 107-156. 
43. Whitelaw, E., et al., Regulated expression of globin chains and the erythroid transcription factor 
GATA-1 during erythropoiesis in the developing mouse. Mol Cell Biol, 1990. 10(12): p. 6596-606. 
44. Xu, X.S., P.M. Glazer, and G. Wang, Activation of human gamma-globin gene expression via 
triplex-forming oligonucleotide (TFO)-directed mutations in the gamma-globin gene 5' flanking 
region. Gene, 2000. 242(1-2): p. 219-28. 
45. Xu, X.S., X. Hong, and G. Wang, Induction of endogenous gamma-globin gene expression with 
decoy oligonucleotide targeting Oct-1 transcription factor consensus sequence. J Hematol Oncol, 
2009. 2(1): p. 15. 
46. Borg, J., et al., Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary 
persistence of fetal hemoglobin. Nat Genet, 2010. 
47. Sankaran, V.G., et al., Human fetal hemoglobin expression is regulated by the developmental 
stage-specific repressor BCL11A. Science, 2008. 322(5909): p. 1839-42. 
48. Sankaran, V.G., et al., Developmental and species-divergent globin switching are driven by 
BCL11A. Nature, 2009. 
49. Zhou, D., et al., KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. 
Nat Genet, 2010. 
50. Tallack, M.R., et al., A global role for KLF1 in erythropoiesis revealed by ChIP-seq in primary 
erythroid cells. Genome Res, 2010. 20(8): p. 1052-63. 
51. Yokochi, T., et al., Monoclonal antibodies detecting antigenic determinants with restricted 
expression on erythroid cells: from the erythroid committed progenitor level to the mature 
erythroblast. Blood, 1984. 63(6): p. 1376-84. 
81 
 
52. Davis, R.L., H. Weintraub, and A.B. Lassar, Expression of a single transfected cDNA converts 
fibroblasts to myoblasts. Cell, 1987. 51(6): p. 987-1000. 
53. Fu, J.D., et al., Direct Reprogramming of Human Fibroblasts toward a Cardiomyocyte-like State. 
Stem Cell Reports, 2013. 1(3): p. 235-47. 
54. Guo, Z., et al., In Vivo direct reprogramming of reactive glial cells into functional neurons after 
brain injury and in an Alzheimer's disease model. Cell Stem Cell, 2014. 14(2): p. 188-202. 
55. Takahashi, K. and S. Yamanaka, Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors. Cell, 2006. 126(4): p. 663-76. 
56. Baek, E.J., et al., In vitro clinical-grade generation of red blood cells from human umbilical cord 
blood CD34+ cells. Transfusion, 2008. 48(10): p. 2235-45. 
57. Fujimi, A., et al., Ex vivo large-scale generation of human red blood cells from cord blood CD34+ 
cells by co-culturing with macrophages. Int J Hematol, 2008. 87(4): p. 339-50. 
58. Ledran, M.H., et al., Efficient hematopoietic differentiation of human embryonic stem cells on 
stromal cells derived from hematopoietic niches. Cell Stem Cell, 2008. 3(1): p. 85-98. 
59. Miller, J.D., et al., Human iPSC-based modeling of late-onset disease via progerin-induced aging. 
Cell Stem Cell, 2013. 13(6): p. 691-705. 
60. Cohen-Barak, O., et al., Stem cell transplantation demonstrates that Sox6 represses epsilon y 
globin expression in definitive erythropoiesis of adult mice. Exp Hematol, 2007. 35(3): p. 358-67. 
61. Xu, J., et al., Transcriptional silencing of {gamma}-globin by BCL11A involves long-range 
interactions and cooperation with SOX6. Genes Dev, 2010. 24(8): p. 783-98. 
62. Yi, Z., et al., Sox6 directly silences epsilon globin expression in definitive erythropoiesis. PLoS 
Genet, 2006. 2(2): p. e14. 
63. Nguyen, T.K., et al., The XmnI (G)gamma polymorphism influences hemoglobin F synthesis 
contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 beta-thalassemia intermedia 
patients. Blood Cells Mol Dis. 
64. Kingsley, P.D., et al., Ontogeny of erythroid gene expression. Blood, 2013. 121(6): p. e5-e13. 
65. Bradner, J.E., et al., Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and 
HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A, 2010. 107(28): p. 
12617-22. 
66. Novershtern, N., et al., Densely interconnected transcriptional circuits control cell states in 
human hematopoiesis. Cell, 2011. 144(2): p. 296-309. 
67. Nolta, J.A., et al., The AFT024 stromal cell line supports long-term ex vivo maintenance of 
engrafting multipotent human hematopoietic progenitors. Leukemia, 2002. 16(3): p. 352-61. 
82 
 
68. Roecklein, B.A. and B. Torok-Storb, Functionally distinct human marrow stromal cell lines 
immortalized by transduction with the human papilloma virus E6/E7 genes. Blood, 1995. 85(4): 
p. 997-1005. 
69. Shimakura, Y., et al., Murine stromal cell line HESS-5 maintains reconstituting ability of Ex vivo-
generated hematopoietic stem cells from human bone marrow and cytokine-mobilized 
peripheral blood. Stem Cells, 2000. 18(3): p. 183-9. 
70. Cowan, C.A., et al., Derivation of embryonic stem-cell lines from human blastocysts. N Engl J 
Med, 2004. 350(13): p. 1353-6. 
71. Lemischka, I., Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2, 
USPTO, Editor 1993: USA. 
72. Cumano, A., et al., Intraembryonic, but not yolk sac hematopoietic precursors, isolated before 
circulation, provide long-term multilineage reconstitution. Immunity, 2001. 15(3): p. 477-85. 
73. Tang, C., I.L. Weissman, and M. Drukker, Immunogenicity of in vitro maintained and matured 
populations: potential barriers to engraftment of human pluripotent stem cell derivatives. 
Methods Mol Biol, 2013. 1029: p. 17-31. 
74. Takahashi, K., et al., Induction of pluripotent stem cells from adult human fibroblasts by defined 
factors. Cell, 2007. 131(5): p. 861-72. 
75. Mali, P., et al., Improved efficiency and pace of generating induced pluripotent stem cells from 
human adult and fetal fibroblasts. Stem Cells, 2008. 26(8): p. 1998-2005. 
76. Sebastiano, V., et al., In situ genetic correction of the sickle cell anemia mutation in human 
induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells, 2011. 29(11): 
p. 1717-26. 
77. Kobari, L., et al., Human induced pluripotent stem cells can reach complete terminal maturation: 
in vivo and in vitro evidence in the erythropoietic differentiation model. Haematologica, 2012. 
97(12): p. 1795-803. 
78. Schlaeger, T., Genetically Corrected Sickle Cell Anemia hiPS Cells, 2013, hESC Core Children's 
Hospital Boston. 
79. Lu, S.J., et al., Directed differentiation of red blood cells from human embryonic stem cells. 
Methods Mol Biol, 2010. 636: p. 105-21. 
80. Yin, P., et al., Transcription factor KLF11 integrates progesterone receptor signaling and 
proliferation in uterine leiomyoma cells. Cancer Res, 2010. 70(4): p. 1722-30. 
81. Gombos, Z., et al., Expression of erythropoietin and its receptor increases in colonic neoplastic 
progression: the role of hypoxia in tumorigenesis. Indian J Pathol Microbiol, 2011. 54(2): p. 273-
8. 
83 
 
82. Kim, B.S., et al., The crucial role of GATA-1 in CCR3 gene transcription: modulated balance by 
multiple GATA elements in the CCR3 regulatory region. J Immunol, 2010. 185(11): p. 6866-75. 
83. Kumar, A., et al., p53 impairs endothelial function by transcriptionally repressing Kruppel-Like 
Factor 2. Arterioscler Thromb Vasc Biol, 2011. 31(1): p. 133-41. 
84. Island, M.L., et al., GATA-4 transcription factor regulates hepatic hepcidin expression. Biochem J, 
2011. 437(3): p. 477-82. 
85. Malumbres, R., et al., LMO2 expression reflects the different stages of blast maturation and 
genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome. 
Haematologica, 2011. 96(7): p. 980-6. 
86. Kim, H.J., et al., Transcription factor Sp1 regulates basal transcription of the human DRG2 gene. 
Biochim Biophys Acta, 2011. 1809(3): p. 184-90. 
87. Cantu, C., et al., Sox6 enhances erythroid differentiation in human erythroid progenitors. Blood, 
2011. 117(13): p. 3669-79. 
88. Liu, S., et al., Haem-regulated eIF2alpha kinase is necessary for adaptive gene expression in 
erythroid precursors under the stress of iron deficiency. Br J Haematol, 2008. 143(1): p. 129-37. 
89. Yu, H.C., et al., Eos negatively regulates human gamma-globin gene transcription during 
erythroid differentiation. PLoS One, 2011. 6(7): p. e22907. 
90. Chen, R.X., et al., Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma 
cells via increasing osteopontin expression. J Exp Clin Cancer Res, 2010. 29: p. 172. 
 
 
 
84 
 
 
 
 
 
 
Chapter 4 
Perspective 
 
  
85 
 
4.1 Research Summary 
 
This thesis furthers our understanding of the developmental maturation of hematopoietic cells, 
specifically hematopoietic stem cells (HSCs) and red blood cells (RBCs), to the definitive fate.  We found 
that the environment both in vivo and in vitro has a significant effect on the emergence and function of 
definitive cells.  In the context of HSC transplants, the hematopoietic environment of the transplant host 
significantly affects the outcome of the transplant with HSCs from different developmental stages.  In 
the context of directly differentiating human pluripotent stem cells (hPSCs) into RBCs, the culture 
environment may lack the cues necessary for the emergence of definitive RBCs. 
HSC transplants using adult and neonatal recipients are established systems we used to highlight 
functional differences between early embryonic and adult-like HSCs.  We quantified the number of HSCs 
in the early embryo with limiting dilution transplants of neonatal recipients.  When unfractionated early 
embryonic tissues were transplanted into neonates, our analysis predicted 1 repopulating cell in the 
para-aortic splanchnopleura/aorta-gonad-mesonephros (PSp/AGM) of 44.8 E9.5 embryos, 2.84 E10.5 
embryos, and 0.96 E11.5 embryos.  Interestingly, the neonatal host is not more permissive for 
engraftment of all HSCs.  Adult-like HSCs, even those from the embryo, preferentially engrafted adult 
recipients.  From limiting dilution transplants, the predicted frequency of HSCs in the Lineage- Sca1+ cKit+ 
CD150+ CD48- compartment of E14.5 fetal liver and adult bone marrow was 4.4- to 13.5-fold lower, 
respectively, with neonatal recipients compared to adult recipients.  We noticed HSCs from the fetal 
liver engrafted neonates better than HSCs from adult bone marrow.  Further evaluation of HSCs residing 
in liver versus bone marrow demonstrated reduced neonatal engraftment from HSCs that had migrate 
to the bone marrow by the time of birth.   
86 
 
We investigated potential mechanisms governing the reduced neonatal engraftment potential 
of adult HSCs.  We showed that adult HSCs exposed to interferon-α, thus forced to enter the cell cycle, 
engrafted neonates better than controls, suggesting proliferation of adult-like HSCs enhances neonatal 
engraftment potential.  We also found that adult HSCs homed mostly to the liver in neonatal recipients 
and to the liver and spleen in adult recipients, which is likely linked to the observed difference in long-
term engraftment potential in the two transplant models.   
Our findings have implications in functionally testing hematopoietic derivates of human 
pluripotent stem cells (hPSCs), as hematopoietic derivatives of hPSCs are generally embryonic [1-3].  We 
evaluated the potential of hPSC derived RBCs to transition to the definitive fate. 
We compared the RBC output of 3 different directed differentiation methods with 11  hPSC lines 
and optimized the most robust and reproducible combination, the Lanza protocol with MSC-iPS1 cells 
[4].  hPSC derived RBCs are primitive with high levels of ε-globin and γ-globin and negligible amounts of 
β-globin.  We attempted to promote a more developmentally mature definitive state by over-expressing 
key erythroid transcription factors BCL11A and KLF1, co-culturing on human fetal liver and bone marrow 
stromal cells, and providing a hypothesized supportive in vivo environment by transplantation into 
neonatal immunodeficient mice producing 3 human cytokines.  Regardless of the approach used, we did 
not detect a significant or consistent change in the ratio of expressed hemoglobins; therefore, we 
concluded the fate of the cells was not altered.  Our results highlight the significant role of the 
environment in properly maturing hematopoietic cells.   
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4.2 Discussion 
 
Current methods of differentiating PSCs yield embryonic cells instead of the largely desired adult 
definitive cells [1, 5-7].  We set out to gain insights into the transition to the adult definitive fate, 
choosing two systems, HSCs and RBCs, with well characterized in vivo counterparts and markers 
distinguishing the embryonic from the definitive cells [8, 9]. 
The gold standard functional measure of definitive HSCs is long-term multi-lineage 
reconstitution upon transplantation into a lethally irradiated wild-type adult mouse, as it most closely 
mimics clinical cases [10-13].  However, this assay may not accurately capture all types of HSCs.  Imaging 
studies suggest the presence of HSCs in the early embryonic tissues at E10.5 and earlier, which have low 
or no engraftment in wild-type adult recipients [14-17].  Interestingly, the PSp/AGM and yolk sac from 
E9.0 to E10.5 engraft immunodeficient adult mice and wild-type neonatal mice suggesting that the 
proper supportive environment is necessary for HSCs to contribute to long-term multi-lineage 
hematopoiesis [18-20].   
Reports from Yoder and colleagues suggested neonatal recipients are permissive for 
engraftment of early embryonic HSCs [19, 20].  We used the neonatal transplant model to quantify the 
number of HSCs present in the PSp/AGM from E9.5 to E11.5.  Our quantification data indicate the 
presence of rare intraembryonic HSCs in approximately 2% of E9.5 embryos.  The frequency of embryos 
with HSCs increases as the embryos continue to develop.  At E11.5 there is at least 1 HSC per embryo, as 
predicted by LDA using neonatal and adult recipients [21].  This quantification paired with imaging 
studies furthers our understanding of the emergence of the earliest definitive HSCs, suggesting that 
HSCs continuously emerge in clusters budding from the ventral floor of the PSp/AGM from E9.5 to E12.   
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The emerging clusters may contain pre-HSCs that are still maturing in response to the embryonic 
environment [22].  The neonatal environment, unlike the adult environment, may pattern pre-HSCs such 
that they are able to contribute to long-term multi-lineage engraftment, but there is a bias towards the 
B-cell lineage, suggesting that the pre-HSC could be related to a described B-cell progenitor that 
emerges directly from the hemogenic endothelium at E9.0  [23].  The B-cell skewing is reduced over two 
days as the pre-HSCs mature into HSCs capable of reconstituting wild-type adult recipients by E11.5.   
One source of variability in the LDA is the conditioning regimen.  We made the conditioning 
regimen of neonates and adults as similar as possible, giving both sub-lethal irradiation with no helper 
cells or the highest tolerated irradiation dose with helper cells.  The number of helper cells used as 
short-term radioprotection in lethally irradiated adult recipients significantly affects engraftment results 
and therefore quantification of HSCs.  Medvinsky’s group reported that a low dose of 20,000 helper cells 
contains an average of 2 HSCs, which reduces competition with the small number of donor HSCs for 
space in the niche  [21, 24].  In our adult transplants, lowering the helper dose 15-fold to 20,000 cells 
resulted in a 10.6-fold increase in the number of predicted HSCs.  Transplanting neonates with helper 
cells resulted in similar or slightly higher engraftment than we observed in neonates that did not receive 
helper cells.  The irradiation dose also affects transplant outcomes.  The sub-lethal neonatal 
conditioning may even result in an underestimation of the HSC frequency as there is less space cleared 
in the marrow and more competition from remaining endogenous cells.  Adult recipients conditioned 
like neonates with sub-lethal irradiation and no helper cells had slightly improved donor chimerism, but 
the neonatal system still proved more permissive for engraftment of HSCs from E10.5 and earlier.  
Although we did not examine the effects of altered conditioning regimens in transplants with adult-like 
HSCs, the substantial disparity between neonatal and adult recipients is likely a result of variations in the 
conditioning regimen and additional elements such as different hematopoietic niches or different 
growth factors. 
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In addition to quantifying the HSCs present in the PSp/AGM of the early embryo, we 
demonstrated that neonatal recipients are not more permissive hosts for adult-like HSCs.  As the current 
gold standard in the field is to define HSCs by transplantation into wild-type adult recipients, our 
findings are critically important, showing the effect of the recipient on the outcome of a transplant.  
Future studies will identify properties of HSCs that preferentially engraft neonates over adults and vice 
versa, which may lead to the discovery of novel hematopoietic stem/progenitor populations in more 
mature tissues like the adult bone marrow.   
Our findings exemplify the selective pressure on donor cells that is created by the transplant 
environment, which significantly affects transplant outcomes and therefore our conclusions about HSC 
biology.  To make correct conclusions from functional HSC transplant studies, we must take into account 
the survival and proliferation needs of donor HSCs and perform transplants with the proper host to 
address the specific experimental question.   
It is very likely that different niches support HSCs in neonates and adults.  While the complexity 
of the adult bone marrow niche is coming into focus, the HSC niches in neonatal liver and bone marrow 
are not well studied [25, 26].  We found that LT-HSCs from the neonatal liver engrafted neonates more 
robustly than LT-HSCs from the neonatal bone marrow, suggesting functional variation in neonatal HSCs.  
We also showed that adult HSCs home to different niches in neonatal and adult recipients, suggesting 
the presence of different hematopoietic niches.  Future studies of the neonatal HSC niche will shed light 
on the differing needs of early embryonic and adult HSCs.  A more exhaustive homing study of short-
term time points would provide insight as to the hematopoietic tissue in neonates and adults that 
supports long-term engraftment from HSCs taken from different developmental stages. 
The presence of a niche that supports the transplanted HSC is critical for long-term engraftment.  
Frenette and colleagues recently identified unique niches within the adult bone marrow for proliferating 
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and quiescent HSCs [26].  Coupled with our data suggesting cycling adult-like HSCs have enhanced 
neonatal engraftment potential, it is likely that neonatal bone marrow contains more niche sites 
supporting proliferating HSCs than quiescent HSCs.  Alternatively, donor HSCs may need to be cycling to 
compete with remaining endogenous HSCs in the sub-lethally irradiated neonates.  Concentrations of 
steel factor in neonatal hematopoietic niches may also play a role in the neonatal engraftment potential 
of adult-like HSCs [27]. 
Our work highlights the important role the host environment plays in HSC transplants.  In 
functionally testing hematopoietic derivatives of hPSCs, it is also necessary to keep the role of the 
environment in mind.  To date, hematopoietic derivatives of hPSCs are embryonic [1-3].  Our work with 
hPSC derived RBCs suggests the in vitro environment may also play a substantial role in the survival and 
differentiation potential of definitive HSCs. 
We tested 11 hPSC lines in 3 published RBC differentiation protocols and found one robust and 
reproducible combination, MSC-iPS1 cells in the Lanza protocol [4].  All hPSC derived RBCs were 
primitive, containing mostly ε-globin and γ-globin with very little, if any, β-globin.  The ratio of expressed 
hemoglobins did not change with co-culture on fetal liver or bone marrow stromal cells or with over-
expression of BCL11A or KLF1.  Single cell analysis did show 1 cell out of 44 with high-levels of β-globin 
mRNA, suggesting the rare emergence or survival of definitive RBCs.  Our data suggest the in vitro 
transition to the definitive fate is a rare occurrence.  There are many possible explanations including:  1) 
the derived RBCs are too primitive to respond to our methods, 2) there are two distinct waves of 
erythropoiesis and additional or different factors are needed to convert from the primitive progenitor to 
the definitive progenitor, or 3) current culture conditions do not support the emergence of definitive 
cells.  These hypotheses can be tested by manipulating more mature cells expressing mostly γ-globin 
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[28] or using our optimized system to screen for additional factors that facilitate the transition to the 
definitive fate.    
Additionally, our data demonstrate primitive RBCs and primitive RBC precursors are unable to 
thrive in neonatal xenografts.  In control transplants with CD34+ enriched cord blood cells, we observed 
engraftment at lower levels than expected from adult recipients, which may be related to our 
observations with adult-like HSCs in congenic murine transplants.  Several potential scenarios could 
explain the lack of engraftment from hPSCs derivatives: 1) transplanted cells may not survive in vivo, 2) 
the cells cannot home to the proper niche, 3) surviving cells may not proliferate and thus are too few to 
detect at analyzed time points, and 4) an engrafting cell may not have been generated in vitro.  Some of 
these hypotheses can be tested with short-term homing studies.  A homing defect is likely not the 
problem as we did not detect engraftment when cells were injected intrahepatically.   
If a definitive HSC did emerge in vitro, it is unlikely to have survived.  Engineering the 
components of an environment supportive of self-renewing definitive HSCs that maintain the potential 
for multi-lineage differentiation is a challenge in the HSC field [29].  Thus, it is not surprising that we are 
unable to generate lineage committed cells of the definitive fate.  Current in vitro cultures may promote 
stress erythropoiesis which up-regulates γ-globin [30-32].  There are two possible explanations for this: 
1) the primitive and definitive precursors are extremely plastic, easily transitioning to the fate best 
supported in a particular environment, or 2) the primitive and definitive precursors have limited 
plasticity to transition from one fate to the other.  With culture conditions supporting the emergence of 
the primitive fate, there would be no chance of a definitive cell emerging even if stimulated with 
transcription factors.   
From the murine model system, we know there are two waves of hematopoiesis, and the 
primitive and definitive waves respond to different environmental stimuli [8, 33, 34].  Analysis of hPSC 
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derived RBCs suggests they are similar to RBCs emerging during yolk sac erythropoiesis, which may be 
too primitive to respond to the added transcription factors or co-cultures [8, 35].  Given that unique 
conditions give rise to primitive and definitive murine hematopoiesis [36-40], we may need an entirely 
different approach to hPSC differentiation to create the proper environment for the rapid emergence of 
definitive precursors.  Alternatives include the carefully crafted differentiation protocol from Keller’s 
group that slowly steers hPSCs towards the definitive hematopoietic fate [41].  The cultures go through 
an early primitive wave then begin to produce potential definitive precursors.  The differentiation may 
be more efficient if the niche was recreated in vitro, promoting developmental maturation through cell-
cell interactions and secreted factors.  Recent reports implicate the Lin28-let-7 axis as a master regulator 
of developmental timing [42, 43].  Modulating the Lin28-let-7 axis during hPSC differentiation may 
provide the molecular signal necessary for the emergence of definitive hematopoietic cells.  It is also 
feasible that the source of difficulty is the starting hPSCs.  β-globin expressing RBCs have been derived 
from mouse PSCs [31, 44], suggesting the degree of pluripotency is the key as mouse PSCs are more 
naïve than hPSCs [45, 46].  More naïve hPSCs, like hLR5 cells, may better differentiate into definitive 
RBCs [47].  Once we understand the process of developmental maturation to definitive hematopoietic 
cells, we should be able to engineer methods to bypass the primitive wave entirely to rapidly produce 
definitive cells.  
 
4.3 Future Directions 
  
Our work demonstrates the impact of the environment or culture conditions on the fate of 
hematopoietic cells.  In the context of murine HSC transplants, HSCs from different stages of ontogeny 
have a preference for different recipients.  There are unanswered questions concerning the differing 
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survival and differentiation needs of HSCs from different stages of development as well as questions 
surrounding different HSC niches and host environments in neonatal and adult recipients.  We focused 
on the properties of adult-like HSCs linked to different recipient preferences, but there is more to be 
learned.  We showed that adult HSCs exposed to interferon-α had enhanced neonatal engraftment 
potential, but we did not see the same result with adult HSCs exposed to 5-FU, suggesting the 
interferon-α effect may be more complex than simply increasing proliferation.  Additionally, we 
demonstrated that adult-like HSCs have reduced neonatal engraftment potential once they migrate 
from the liver to the bone marrow.  It has yet to be determined if this is caused by the bone marrow 
microenvironment, perhaps related to the expansion of α-HSCs, or if there are cell intrinsic changes 
reducing neonatal engraftment potential that coincide with migration to the bone marrow.   
There is also the question of the mechanism causing early HSCs to preferentially engraft 
neonatal recipients.  Many avenues of investigation could provide insights.  The neonatal preference 
may be an immunologic phenomenon, which could be studied by closely examining MHC markers on 
early embryonic HSCs versus adult-like HSCs or by transplanting neonatal mice from an 
immunodeficient strain [48].  There are obviously differences in cytokines and growth factors between 
neonatal and adult recipients.  Neonates have lower cytokine levels that may not be sufficient to invoke 
a response from adult HSCs, which thrive in an environment with high cytokine levels [49].  Also, which 
niche and tissue early embryonic HSCs home to in neonatal and adult recipients is unknown.  Studies in 
that vein would provide important information about the environment that supports the survival, 
maturation, and differentiation of the earliest HSCs, which may also provide insights into the niche that 
gives rise to the earliest HSCs in the embryo in addition to the proper culture environment to generate 
definitive hematopoietic cells in vitro. 
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Our work has implications for HSC transplants in the clinic and functionally assaying in vitro 
derived HSCs.  In the clinic, donor cells for HSC transplant commonly come from umbilical cord blood, 
adult bone marrow, or adult mobilized peripheral blood [50-52].  To see if our findings translate to the 
human hematopoietic system, clinical data could be retrospectively analyzed correlating the source of 
donor cells, the age of the recipient, and engraftment outcomes.  It would also be interesting to see if 
embryonic cells from other hematopoietic lineages, specifically RBCs, prefer neonatal hosts for clinically 
relevant procedures like transfusions.  
In the time since this body of work was started, new differentiation methods have been 
developed to derive RBCs from hPSCs.  Of particular interest is the work from the Orkin group that 
generated RBCs expressing only γ-globin [28].  It would be interesting to see if those cells or their 
precursors, which are more definitive than the cells we analyzed, could be forced to complete the 
transition to the adult definitive fate and express β-globin.  To reach the adult definitive state, the 
chromatin may need to be made more accessible by adding epigenetic modifiers during differentiation 
[53, 54].  
We highlighted the role of the environment and culture conditions on the self-renewal and 
differentiation capabilities of hematopoietic stem/progenitor cells, but there is much left to discover in 
the mechanisms governing the observed phenomenon.  A complete understanding of the transition 
from the primitive fate to the definitive fate will not only teach us about a basic biological switch but 
will also give us the knowledge to mimic nature to generate cells for in vitro disease modeling, drug 
screening, and cell therapies.   
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